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Summary 
Parkinson’s disease (PD) is a common neurodegenerative disease clinically characterized 
by bradykinesia, rigidity and resting tremor. PD is characterized pathologically by the 
degeneration of nigrostriatal dopaminergic neurons and the presence of Lewy bodies 
containing a small protein, alpha-synuclein. Mutations in Leucine-rich repeat kinase 2 gene 
(LRRK2) are associated with familial and sporadic Parkinson’s disease (PD). LRRK2 is a 
complex protein that consists of multiple domains executing several functions, including 
GTP hydrolysis, kinase activity, and protein binding. There are many single nucleotide 
alterations covering LRRK2's functional domains, but the main missense mutations that 
clearly segregate with PD in large family studies, cluster within the enzymatic domains. The 
G2019S mutation falls in the activation loop of the kinase domain generating a 2-fold 
increase in LRRK2 kinase activity. Although patients with LRRK2 mutations usually 
respond to levodopa therapy, this treatment is only symptomatic and it does not cure the 
cause of the disease. In particular, LRRK2 mutations lead to neuronal cell death and toxic 
protein aggregates and LRRK2 kinase activity seems to be responsible for the observed 
neurotoxicity. Our previous research pointed out that LRRK2 acts at the presynaptic site 
where interacts with synaptic vesicles (SV) and presynaptic proteins together with which it 
controls SV trafficking in a kinase depended manner. Our recent data indicate NSF not only 
as an interactor but also as a substrate for LRRK2 kinase activity in vitro. In the present work 
we analyze how LRRK2 increased kinase activity conferred by the PD related G2019S 
mutation influences the neuronal functions. We investigated whether G2019S mutation might 
affect presynaptic function in short term and substrate clearance in long term. Next, we 
evaluated the feasibility of two potential therapeutic strategies: the first implies the use of 
LRRK2 kinase inhibitors while the second focuses on treatment ameliorating protein 
degradation via induction of autophagy. By dynamic studies of SV release in cultured 
neurons of human LRRK2 G2019S (GS) overexpressing mice and in breed wild-type mice, 
we found that the increase of LRRK2 kinase activity positively correlates with an increase in 
the endocytosis rate of the SV. Moreover, we report also an impairment in the complexity of 
the neuronal tree of the GS neurons that depends on both increased protein level and kinase 
activity. We recently reported that LRRK2 phosphorylates NSF at threonine 645 inducing an 
increase in NSF’s ATP hydroxylation rate that determine an increase in the SNARE 
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disassembly. Moreover, we found that aged GS mice show aberrant NSF protein 
accumulation and motor as well as cognitive impairment. We report also that the chronic 
treatment with trehalose, an autophagy inducing molecule, partially recovered the motor 
phenotype and NSF aggregation proposing it as an interesting therapeutic strategy. 
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1 Introduction 
1 Parkinson’s Disease 
1.1 Historical review 
In 1817, James Parkinson, an English surgeon, and political activist, described for the 
first time the symptoms of the disease that today bears his name. In his work, “An Essay on 
the “Shaking Palsy” he reports his observation on six individuals three of which were his 
patients. He referred to the disease as paralysis agitans or shaking palsy, identifying episodes 
of resting tremors and of tremors with motion. He originally charged these episodes to 
possible lesions in the cervical spinal cord and encouraged others to study this condition 
(McCall 2003). It was not until 1872 that the “shaking palsy” was named Parkinson disease 
by the French doctor Jean-Martin Charcot, who also made the distinction between rigidity, 
weakness and bradykinesia (Lees 2007). In 1912, Fritz Heinrich Lewy identified the protein 
aggregates that define Parkinson disease (PD) (Goedert et al. 2012). Lewy described the 
characteristic inclusions in the dorsal motor nucleus of the vagus nerve, the basal nucleus of 
Meynert, the globus pallidus, the lateral nucleus of the thalamus, and the periventricular 
nucleus of the thalamus. The inclusions described by Lewy were eosinophilic and were 
insoluble in alcohol, chloroform, and benzene, consistent with the presence of a major protein 
component.  
In 1919, Tretiakoff reported the presence of Lewy bodies in the substantia nigra in PD 
(Kapp 1992). He also showed degeneration of the substantia nigra and postulated a 
connection between nerve cell loss, rigidity, and tremor. In 1938, Rolf Hassler (1914–1984) 
confirmed Tretiakoff’s observation that degeneration of the substantia nigra was the cause of 
Parkinsonism. He also demonstrated the focal distribution of pathology, with the most 
pronounced nerve cell loss being found in the caudal and ventrolateral parts of the substantia 
nigra (Hassler 1938). The fact that nerve cells in the ventrolateral part of the pars compacta of 
the substantia nigra are severely affected in PD is now well established. These cells project 
mainly to the dorsal putamen, the most dopamine depleted region of the striatum in PD 
(Goedert et al. 2012).  
Nowadays PD represents the second most common neurodegenerative disorder of aging. 
It affects 2% of the population over 60 years of age and occurs at an incidence of 16-19 in 
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100 000 individuals per year (Rudzińska et al. 2013) 
1.2 Anatomy of PD 
The basal ganglia are one of the areas in the encephalon involved in movement’s control 
influencing the activity of the superior motorneurons. They are a subgroup of nuclei that 
include the caudate, putamen and globus pallidus. Their activity is associated with the one of 
other two structures: substantia nigra in the mesencephalon and the ventral subthalamic 
nucleus of the thalamus. All of these structures create a subcortical circuit that connects the 
inputs from cortical area to the superior motor neurons from the primary motor cortex, 
premotor cortex and brain stem.  The canonical view of this circuit proposes the model of a 
direct and an indirect pathway (Fig. 1). In the first, the cortical activation produces a release 
of glutamate that activates caudate/putamen’s MSNs (medium spiny neurons). These are 
GABAergic cells projecting and inhibiting the substantia nigra pars reticulate (SNpr) and the 
globus pallidus Pars Interna (GPi). The inhibition of the GABAergic cells of SNpr leads to a 
disinhibition of the thalamic glutamatergic neurons, which receive SNpr input and project to 
the cortex. The behavioral result of this chain of events is locomotor activation/movements. 
The indirect pathway activates the striatopallidal MSNs, which projecting to the SNpr via the 
globus pallidus pars externa (GPe) and the subthalamic nucleus (STN), inhibits the 
GABAergic neurons of the GPe. This leads to a disinhibition of the glutamatergic neurons of 
the STN that activates the SNpr GABAergic neurons projecting to the thalamus. Ultimately, 
this effect results in the reduction of locomotor activity and movement. These pathways 
interact in parallel and have two opposite actions: the activation of the direct way allows to 
basal ganglia to start the voluntary movement while the activation of the indirect way limits 
it, inhibiting abnormal movements.  
 
Figure 1. Schematic representation of the direct and indirect pathways in physiological conditions (a) and Parkinson’s 
disease (b) Adapted from (Calabresi et al. 2014) 
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GABAergic neurons of the GPe, leading to a disinhibition of the 
glutamatergic neurons of the STN. The increased discharge of these 
excitatory STN neurons in turn activates the SNpr GABAergic neu-
rons projecting to the thalamus. Ultimately, this effect results in the 
reduction of locomotor activity and movement (Fig. 1).
In addition to their distinct projections, MSNs of the direct and 
indirect pathway are characterized by the differential expression of 
dopamine (DA) receptors. D1 DA receptors are expressed by direct 
pathway MSNs, whereas D2 receptors are expressed by indirect path-
way MSNs. These two receptors are associated with distinct G proteins 
that are linked to different intracellular signaling pathways and lead 
to different biochemical responses following DA receptor activation. 
This neurochemical segregation is considered to be further support 
for a dichotomous effect of the activation of the direct and indirect 
pathways10,11.
Experimental consequences of the model
The direct/indirect pathways model has been widely used to explain 
experimental findings, build models of BG disorders, and explain 
therapeutic effects of both pharmacological and neurosurgical treat-
ments. Distinct, and even opposite, roles of these two pathways in 
regulating several physiological functions involving the BG, such as 
basal locomotor activity and motor responses to drugs of abuse and 
antipsychotic agents, have even been postulated12,13. In particular, 
the selective loss of the striatal signaling protein DA- and cAMP-regulated 
phosphoprotein 32 kDa (DARPP-32) in direct pathway MSNs reduces 
basal and cocaine-induced locomotion, and, in a rodent model of 
PD, abolishes dyskinetic behavior in response to levodopa (L-DOPA), a DA 
precursor that is widely used as a form of therapy for PD. Conversely, 
a loss of DARPP-32 in indirect pathway MSNs augments locomo-
tor activity and reduces cataleptic response to the antipsychotic 
drug haloperidol12.
D1 striatonigral and D2 striatopallidal MSNs have typically been 
considered as homogeneous populations regarding their somatoden-
dritic morphology, although neurochemical differences have been 
found in these neuronal subtypes2,14. In fact, SNpr-projecting MSNs 
express substance P, dynorphin and D1 DA receptors, whereas GPe 
projecting MSNs express enkephalin and D2 DA receptors. The intro-
duction and use of D1 and D2 bacterial artificial chromosome (BAC) 
transgenic mice13 to distinguish MSNs without post hoc analyses led 
to the identification of further possible differences between these two 
populations. Electrophysiological studies15,16 found differences in the 
excitability of striatal D1 and D2 MSNs, with D2 MSNs consistently 
firing at higher frequencies, as well as differences in resting membrane 
potential, input resistance and rheobase current. Moreover, experi-
ments using two-photon laser-scanning microscopy in identified 
MSNs showed that the dendrites of D2 MSNs are more excitable than 
those of D1 MSNs, and that DA depletion augments this asymmetry17. 
Notably, three-dimensional reconstructions revealed a significantly 
greater total dendritic length of D1 versus D2 MSNs, suggesting that 
dendritic anatomy might contribute to differences in MSN excitabil-
ity18. Finally, striatal DA denervation has been found to reduce spines 
and glutamatergic synapses, potentially via dysregulation of a Ca2+ 
channel implicated in the pathophysiology of PD, on striatopallidal, 
but not striatonigral, MSNs19.
The introduction of D1 and D2 BAC transgenic mice has also pro-
vided new results regarding features of striatal synaptic plasticity and 
its possible functional implications. Although previous studies have 
demonstrated the expression of activity-dependent long-term depres-
sion (LTD) in the large majority of MSNs, suggesting an absence of 
neuronal segregation between the two pathways20–23, BAC-mediated 
targeting of direct and indirect pathways yields a different result. 
Kreitzer and Malenka16 showed a selective D2 receptor activation– 
dependent LTD in MSNs of the indirect pathway. Notably, this form 
of synaptic plasticity was absent in PD rodent models and was res-
cued by D2 receptor stimulation. To determine whether synaptic 
plasticity could be unidirectional in D1 and D2 receptor–expressing 
MSNs, spike timing–dependent plasticity was also investigated in 
brain preparations from DA receptor BAC transgenic mice. This 
study showed that, although DA has a complex and complementary 
role in these two types of MSNs to ensure bidirectional plasticity in 
physiological conditions, this role is altered in mouse models of PD 
and only unidirectional changes in plasticity occur24.
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Figure 1 Schematic representation of the direct/indirect pathway classical 
model in the physiological condition and in Parkinson’s disease. (a) In the 
physiological condition, DA arising from the SNpc is thought to activate 
D1-expressing striatal MSNs of the direct pathway (red lines) and to inhibit 
D2-expressing striatal neurons of the indirect pathway (blue lines). The 
output nuclei GPi and SNpr project to the thalamus, which in turn sends 
efferents that complete the cortico-basal ganglia-thalamo-cortical loop. 
(b) In Parkinson’s disease, degeneration of nigral neurons reduces DA 
receptor stimulation in striatal MSNs. The imbalance between direct and 
indirect pathways results into abnormal activation of output nuclei and over-
inhibition of thalamic neurons projecting to the cortex.
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plasticity could be unidirectional in D1 and D2 receptor–expressing 
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Figure 1 Schematic representation of the direct/indirect pathway classical 
model in the physiological condition and in Parkinson’s disease. (a) In the 
physiological condition, DA arising from the SNpc is thought to activate 
D1-expressing striatal MSNs of the direct pathway (red lines) and to inhibit 
D2-expressing striatal neurons of the indirect pathway (blue lines). The 
output nuclei GPi and SNpr project to the thalamus, which in turn sends 
efferents that complete the cortico-basal ganglia-thalamo-cortical loop. 
(b) In Parkinson’s disease, degeneration of nigral neurons reduces DA 
receptor stimulation in striatal MSNs. The imbalance between direct and 
indir ct pathways r sults into abnormal activation of output nuclei and over-
inhibition of thalamic neurons projecting to the cortex.
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The overall activity of the direct/indirect way is finely controlled by another circuit 
belonging to the basal ganglia system that includes the dopaminergic cells from the substantia 
nigra pars compacta (SNc). The MSNs project directly to SNc and receive SNc wide 
dopaminergic afferents. The dopamine effect on the MSNs is rather complex as it has a dual 
action according to the receptor that it binds. The D1 and D2 dopaminergic receptors belong 
to the family of seven trans-membrane domain G proteins bound receptors, and the 
substantial difference between them is that D1 activation mediates the activation of the G 
proteins that stimulates the production of cAMP, while the D2 receptors inhibits it. 
Apparently the MSNs involved in the direct way express D1 receptors while the ones 
involved in the indirect way express D2 receptors. Therefore, dopamine release from SNc 
stimulates the direct way through the D1 receptors and inhibits the indirect way through the 
D2 receptors.  
In pathological situations as PD (Fig 1b), the loss of dopaminergic neurons allows the 
reduction of the direct pathway and the increase of the indirect one. The result is an addition 
of inhibition on the basal ganglia that reduce that probability that the superior cortical motor 
neurons are correctly activated by the thalamic ones. This explains why the majority of PD 
patients have a reduced ability in movement initiation and once started also in its ending.   
1.3 Genetics of PD 
Despite the fact that for many years Parkinson’s disease was considered a sporadic 
disease caused by synergistic environmental factors, alterations in various genes are now 
associated with the development of this disease. These were identified through unbiased 
research strategies that rely on the systematic scanning of the entire human genome without a 
priori hypotheses on the nature of the causal gene or the pathogenetic mechanisms (Vincenzo 
Bonifati 2014). Although most of the PD-related genes do not have a complete penetrance 
and a clear Mendelian inheritance is rarely seen, GWAS studies identified five causal PD 
genes: SNCA, leucine-rich repeat kinase 2 (LRRK2), parkin RBR E3 ubiquitin protein ligase 
(PARK2), PTEN-induced putative kinase 1 (PINK1), and Parkinson protein 7 (PARK7). 
Comparable family-based studies have also successfully identified genes for juvenile 
Parkinson syndromes, including ATPase type 13A2 (ATP13A2), phospholipase A2 group 6 
(PLA2G6), and F-box protein 7 (FBXO7)(Verstraeten, Theuns, and Van Broeckhoven 2015; 
Vincenzo Bonifati 2014). Mutations in eukaryotic translation initiation factor 4 gamma 1 
(EIF4G1) were also identified, but its role in PD etiology is heavily debated as a remarkably 
high number of non penetrant EIF4G1 mutation carriers have been reported (Schulte et al. 
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2012; Nuytemans et al. 2013). The genetics of PD was revolutionized by recent innovation of 
the sequencing strategy that lead to the identification of six more genes for PD and 
Parkinson-plus syndromes: [vacuolar protein sorting 35 homolog (VPS35), dnaJ homolog 
subfamily C member 13 (DNAJC13), dnaJ homolog subfamily C member 6 (DNAJC6), 
ATPase H+ transporting lysosomal accessory protein 2 (ATP6AP2), synaptojanin 1 (SYNJ1), 
and coenzyme Q2 4-hydroxybenzoate polyprenyltransferase (COQ2)(Verstraeten, Theuns, 
and Van Broeckhoven 2015). 
The discovery of genes mutated in PD and functional studies on their protein products 
have provided new insights into the pathologic events leading to neurodegeneration, 
proposing interconnected molecular pathways that may be deranged in all forms of PD. The 
better understanding of these events can pave the way to elaborate targeted therapies aimed at 
disease prevention and cure. 
1.3.1 Autosomal dominant genes in PD 
Nineteen loci that segregate with familial forms of the disease have been reported, 
collectively suggesting that monogenic PD accounts for 5–10% of all PD cases (Cookson 
2015). Mutations in three genes (SNCA, LRRK2, VPS35) are conclusively established as a 
cause of autosomal dominant forms of PD while evidence for a fourth gene, EIF4G1, remains 
inconclusive. Last, heterozygous mutations in the GBA gene are important and strong risk 
factors for PD and diffuse Lewy-body disease (DLB).  
In the following sections the identified genes in autosomal dominant PD will be briefly 
reviewed.  
1.3.1.1 Alpha synuclein 
In 1996, the first locus for autosomal dominant PD was mapped to chromosome 4q21-
q23. Years later missense point mutation in SNCA gene, that encodes alpha-synuclein 
protein, were reported. The amino acidic substitution Ala53Thr (A53 T) was the first to be 
documented, present in a series of families from Greek and Italian descent (Polymeropoulos 
et al. 1997) followed by A30P present in a German family (Kruger et al. 1998) and E46K in 
several Basques families (Zarranz et al. 2004). Other PD-associated mutations involve SNCA 
gene multiplication (triplication or multiplication) indicating that higher levels of the normal 
protein can cause damage to the brain through a gain of toxic function (Cookson 2012; 
Sundal et al. 2012). Moreover, common variants at the SNCA locus are risk factors for PD, 
which are not strong enough to cause a Mendelian inheritance but increase the risk in 
developing PD by about 20-40% over the live time of an individual (Cookson 2012).  
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Alpha-synuclein is a 140 amino acid presynaptic enriched protein that acts in 
conjunction with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) proteins to regulate neurotransmitter release (Hunn et al. 2015).  It belongs to the 
family of synucleins formed by alpha, beta, and gamma-synuclein. These are highly 
homologous proteins that bind to phospholipids via alpha helices and play a role in dopamine 
release (Senior et al. 2008; Janezic et al. 2013). 
 Alpha-synuclein does not assume a predictable structure in aqueous solution, thus is has 
been commonly described as an intrinsically disordered monomer of approximately 14 kDa, 
conformation that has been recently confirmed by the studies of Burrè et al that reported the 
occurrence of acetylated alpha-synuclein monomer with an apparent molecular weight of 
around 16 kDa (Burré et al. 2013).  Nonetheless, other studies focused on the definition of the 
physiological form of this protein reported a predominant endogenous species of 55-60kDa 
that can be an alpha-synuclein tetramer (Bartels, Choi, and Selkoe 2011). Even though the 
true physiological conformation of alpha-synuclein remains enigmatic there is an 
overwhelming amount of studies that indicates that accumulation of alpha-synuclein in 
insoluble aggregates such as fibrils is neurotoxic and give rise to deleterious effects in DA 
neurons (Tokuda et al. 2010; Winner et al. 2011; Rockenstein et al. 2014; Janezic et al. 
2013). The more recent discovery that a-synuclein aggregates develop in dopaminergic 
neurons transplanted in the brain of PD patients, and further data from in vitro and in vivo 
animal studies, suggest that misfolded a-synuclein conformers have prion-like properties, can 
induce a cascade of protein misfolding, and spread from cell to cell in the brain (reviewed in 
(Olanow and Brundin 2013). These recent, important evidence needs to be taken in 
consideration and to be incorporated into all theories of pathogenesis in a way that also fits 
with the results of the genetic studies (Bonifati et al. 2013). 
1.3.1.2 LRRK2 
In 2002, the PARK8 locus on chromosome 12q12 was linked with PD in a large 
Japanese family (Funayama et al. 2002). This linkage was later confirmed in PD families of 
European descent and the first mutations identified were R1441G, R1441C, Y1699C and 
I2020T (Paisán-Ruíz et al. 2004; Zimprich et al. 2004). Shortly after that, the LRRK2 
G2019S mutation was identified in the kinase domain (Nichols et al. 2007). However, 
Gly2019Ser has strongly incomplete penetrance, which explains why this founder mutation is 
detectable in patients with familial but also in some with sporadic PD (Bonifati 2014). The 
frequency of this mutation is different across the populations and is most prevalent in the 
Middle East and North Africa. The frequency decreases with distance from the 
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Mediterranean (Bardien et al. 2011). 
PD patients who are carriers of LRRK2 mutations mainly suffer from Parkinsonism with 
clinical features indistinguishable from sporadic idiopathic late-onset PD. They present 
dopaminergic neuronal loss and gliosis in the substantia nigra, and classical LBs are found in 
the majority of them. However, in some cases only tau-positive or ubiquitin- positive 
inclusions are seen (Sundal et al. 2012; Bonifati 2014). 
LRRK2 is a large protein with seven different domains harboring over 100 various 
provisional mutations (Sundal et al. 2012). The physiological function of LRRK2 is still 
unknown, but it was linked to vesicular trafficking (Piccoli et al. 2011; Parisiadou et al. 2014; 
Piccoli et al. 2014), degradation of proteins and organelles by the autophagy-lysosome 
pathways (MacLeod et al. 2013; Alvarez-Erviti et al. 2010), and to neuroinflammation and 
innate immunology (Gardet et al. 2010). The possible mechanisms through which mutated 
LRRK2 leads to cellular dysfunction might be related to an exaggeration of its normal 
function or gain of abnormal function (Dachsel et al. 2011).    
Due to the overlap between LRRK2 parkinsonism and idiopathic PD, understanding the 
effect of the mutated LRRK2 gene on disease pathogenesis has enormous potential to 
generate insights into the mechanisms of PD and the development of new therapeutic agents 
(Sundal et al. 2012). 
1.3.1.3 VPS35 
In 2011 Vilarino-Guell et al. and Zimprich et al., using next-generation sequencing 
technology identified a missense mutation (p.Asp620Asn) in the vacuolar protein sorting 35 
(VPS35) located on chromosome 16p12.1-q12.1. (Vilariño-Güell et al. 2011; Zimprich et al. 
2011). This mutation was described as a novel autosomal dominant cause of PD after exome 
sequencing in affected relatives pairs from large families of Austrian and Swiss origins, 
respectively. The disease onset for these families was 52 years (range 37–72 years), and the 
phenotype associated with the Asp620Asn mutation is that of typical PD: asymmetric onset, 
good L-dopa response, and motor complications. The penetrance was incomplete and age 
dependent (Bonifati 2014).   
VPS35 encodes a subunit of the retromer complex, which is involved in membrane 
trafficking between endosomes and the trans-Golgi network (Hunn et al. 2015; Bonifati 
2014). More recently VPS35 mutations have been shown to impair autophagy and cause SNc 
neurodegeneration when expressed in rats (Zavodszky, Seaman, and Rubinsztein 2014). 
Thus, the discovery of VPS35 mutations implicates the dysfunction of retromer in 
neurodegenerative processes opening yet another novel pathway of exploration for 
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therapeutic interventions. 
1.3.1.4 GBA 
The most recently identified dominant inherited mutation linked to the development of 
PD is in the glucocerebrosidase gene (GBA), initially described in patients who suffer from 
Gaucher’s disease, a lysosomal storage disease. Patients affected by this disease are 
homozygous for mutations in GBA while the ones who carry heterozygous GBA mutation 
have an increased risk in developing PD. For this reason that some authors consider GBA a 
dominant causal PD gene with reduced penetrance (Anheim et al. 2012; Sidransky, 
Samaddar, and Tayebi 2009)..  
Some mutations are prevalent in specific ethnic groups, such as the Asn370Ser mutation 
among Ashkenazi Jews. The patients with GBA pathogenic mutations have typical PD with 
possibly a slightly earlier onset age (Bonifati  2014).  
GBA encodes glucocerebrosidase, a lysosomal hydrolase that cleaves the b-glucosyl 
linkage of glucosylsphingosine and glucosylceramide. Reduced glucocerebrosidase activity is 
correlated with alpha-synuclein accumulation in sporadic PD (Murphy et al. 2014). 
1.3.2 Autosomal recessive genes in PD 
Patients bearing homozygous mutations in parkin (PRKN, PARK2), PTEN induced 
putative kinase 1 (PINK1, PARK6), and Parkinson protein 7 (DJ-1, PARK7) genes, develop 
early onset PD, usually without atypical signs (Kitada et al. 1998; Enza Maria Valente et al. 
2004; V. Bonifati et al. 2003). Also recessive mutations in ATPase type 13A2 (ATP13A2) 
have been associated with the development of juvenile-onset, levodopa-responsive 
parkinsonism (Ramirez et al. 2006). Recently other recessive mutations were reported in 
patients with juvenile levodopa-responsive dystonia-parkinsonism. Among them, 
phospholipase A2, group VI (PLA2G6), F-box only protein 7 (FBXO7), DNAJC6 and 
SYNJ1 (Paisán-Ruiz et al. 2012; Zhao et al. 2013; Krebs et al. 2013).   The last two encode 
for auxilin respectively synaptojanin that are two proteins with close roles in the post-
endocytic recycling of synaptic vesicles (Bonifati 2014).  
    In the following sections, the role of the first four genes related with recessive PD 
development will be briefly presented. 
1.3.2.1 Parkin 
PARK2 contains 12 exons that encode the 465 amino acid protein, Parkin (Kitada et al. 
1998). Mutations in this protein are quite common and explain up to half of the cases with a 
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clinical diagnosis of familial PD compatible with recessive inheritance and disease onset 
before the age of 45 years, and also ~15% of the sporadic cases with onset before 45 
(Vincenzo Bonifati 2014).  The first mutation identified was a homozygous deletion of exon 
3-7 (Kitada et al. 1998) followed by other deletions or point mutations that cause PARK2 
protein loss of function (Hattori et al. 1998; Hattori et al. 1998; Leroy et al. 1998). 
The parkin protein is a cytosolic protein belonging to the family of the RING–between-
RING (RBR) E3 ubiquitin ligases (Seirafi, Kozlov, and Gehring 2015). It consists of an 
amino-terminal ubiquitin-like (Ubl) domain and four zinc-coordinating RING-like domains: 
RING0, RING 1, IBR, RING2. The Ubl domain is responsible for substrate recognition, 
proteasome association and regulation of parkin levels and activity while the RING domains 
are responsible for the ubiquitin ligase-transferase activity (Hristova et al. 2009; Shimura et 
al. 2000). The E3 ligase proteins are responsible of covalent attachment of ubiquitin and 
ubiquitin chains to lysine residues or the N-terminal amino group of a substrate protein 
targeting it for proteasomal degradation. Furthermore, mono-ubiquitination is involved in 
other cell processes, such as regulation of gene expression and protein sorting, autophagy 
signaling and lysosomal degradation.  
Parkin activity is tightly controlled by multiple mechanisms of auto inhibition centered 
on the Ubl domain and on binding partners that bind the Ubl domain. However, parkin can be 
activated under different conditions such as depolarization of mitochondria or epidermal 
growth factor signaling. Once activated, it ubiquitinates a variety of cytosolic and outer 
mitochondrial membrane proteins (Sarraf et al. 2013). The ubiquitination of mitochondrial 
membranes signals the recruitment of the autophagosome and proteasome machinery to 
initiate the selective autophagic removal of the damaged organelle (mitophagy) (Narendra et 
al. 2008). 
The disease-causing mutations, in line with a loss-of-function pathological mechanism 
associated with the autosomal recessive inheritance, abolishes the ubiquitin ligase activity. 
The loss of the Parkin function might lead to loss of quality control pathway and 
accumulation of impaired mitochondria, which are thought to be a source of toxic reactive 
oxygen species (ROS) and contribute to neuronal cell death and PD (Seirafi, Kozlov, and 
Gehring 2015). 
1.3.2.2 PINK1 
In 2001 the analysis of a large Italian pedigree revealed mutations on chromosome 1 at 
the PARK6 locus (E. M. Valente et al. 2001; E. M. Valente et al. 2002) leading to the 
discovery of the second gene involved in early-onset PD. These PARK6 mutation patients 
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had symptoms clinically identical to those of patients with sporadic forms of PD (Bentivoglio 
et al. 2001; E. M. Valente et al. 2002). The PARK6 gene encodes a 581 amino called protein 
acid phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) (Enza Maria 
Valente et al. 2004). The protein sequence reveals a C-terminal kinase domain and a 
mitochondrial targeting sequence at the N-terminus, suggesting that it is imported into the 
mitochondria. In fact, as shown by Valente et al., PINK1 has mitochondrial localization in 
cells (Enza Maria Valente et al. 2004), which supports the involvement of mitochondrial 
dysfunction in the pathophysiology of PD. 
There is a consistent amount of cell biology studies that report that PINK1 acts upstream 
of Parkin and is required for Parkin activation and recruitment to depolarized mitochondria, 
to mediate the selective autophagic removal of the damaged organelle (mitophagy)(Narendra 
et al. 2008). The precise mechanism is not yet clear, but it is thought that PINK1 accumulates 
specifically on damaged mitochondria flagging them for elimination. What seems to 
difference a healthy mitochondrion from a damaged one is PINK1 degradation. In steady 
state conditions, PINK1 is imported into the inner mitochondrial membrane (IMM) through 
Transport of the Outer Mitochondrial Membrane (OMM) TOM and TIM complex of the 
inner mitochondrial membrane (IMM), where it is cleaved by the mitochondrial processing 
peptidase (MPP) (Greene et al. 2012). Subsequently. PINK1 is cleaved in its hydrophobic 
domain spanning the inner mitochondrial membrane by presenilin-associated rhomboid-like 
protein (PARL) (Meissner et al. 2011). This cleavage generates a 52 kDa, an N-terminal-
deleted form of PINK1 (Meissner et al. 2011) that is released in the cytosol where it is 
recognized by its E3 ubiquitin ligase and send to the proteasome for degradation (Yamano 
and Youle 2013). In the presence of mitochondrial depolarizing agents, OXPHOS inhibitors, 
genetic or environmental stresses, and even unfolded proteins the mitochondrial import 
through the TIM complex is disrupted. This prevents PINK1 import in the IMM and its 
cleavage by MPP and PARL leading to accumulation of uncleaved PINK1 on the OMM 
(Lazarou et al. 2012; Okatsu et al. 2013). Therefore, upon mitochondrial damage, PINK1 
becomes stabilized on the OMM, and from there it recruits Parkin to mitochondria and 
activates Parkin’s E3 ubiquitin ligase activity.  
But how a mitochondrial protein can recruit and activate a cytosolic protein? 
In the first step, the selective accumulation of PINK1 on the damaged mitochondrion 
leads to the phosphorylation of low, basal levels of ubiquitin or Parkin present on it 
(Ordureau et al. 2014; Koyano et al. 2014; Kane et al. 2014). This acts as positive effector as 
both ubiquitin and Parkin phosphorylation increase Parkin ubiquitin ligase activity (Ordureau 
et al. 2014; Koyano et al. 2014; Kane et al. 2014).  
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In fact, the studies of Kane et al., Kazlauskaite et al., Koyano et al., indicate that PINK 1 
not only phosphorylates Parkin in its Ubl domain at Ser65 leading to its activation but also 
ubiquitin at Ser65. Moreover, Ser65 phospho-ubiquitin derepresses Parkin E3 ligase activity 
(Kane et al. 2014; Kazlauskaite et al. 2014; Koyano et al. 2014). Also, they report that 
phosphomimetic mutants of ubiquitin Ser65Asp are sufficient for Parkin activation while 
Parkin Ser65Asp are not (Kane et al. 2014; Kazlauskaite et al. 2014), indicating that ubiquitin 
phosphorylation is a condition sine qua non, in Parkin activation. The study of Ordureau et 
al., support the hypothesis of a positive loop of activation generated by the phosphorylation, 
centered in changes of binding affinity. In fact they report that phospho-ubiquitin binds to 
Ser65 phosphorylated Parkin with 21 times higher affinity that to Parkin (Ordureau et al. 
2014).  
There are records of other substrates of PINK1 involved in mitophagy such as Miro1, 
mitofusin2 (Mfn2) that upon phosphorylation at Ser195 and, Thr111 and Ser 442, 
respectively follows the Parkin-mediated proteasomal degradation pathway (Wang et al. 
2011; Chen and Dorn 2013). 
The central role of PINK1 kinase activity in mitophagy makes it a target for therapeutic 
approaches. In a recent study, it was reported that kinetin triphosphate, an ATP analog, 
rescues kinase activity of a patient mutant form of PINK1 and increases wild-type PINK1 
activity, revealing a new way to drug the PINK1/Parkin pathway (Hertz et al. 2013). 
1.3.2.3 DJ-1 
In 2003, the DJ-1 gene was identified as PARK7. Mutations in PARK7 are associated 
with autosomal recessive early-onset PD. Several mutations of DJ-1 were found in familial 
forms of PD. The point mutations L166P and M26I of DJ-1 have been reported to cause DJ-1 
destabilization and loss of function (V. Bonifati et al. 2003). DJ-1 is a multifunctional protein 
that is involved in various physiological processes such as transcriptional regulation, 
antioxidative defense, and mitochondrial function and signal transduction and dopamine 
homeostasis (Waak et al. 2009; Zhou and Freed 2005). In fact, it was first identified as an 
oncogene that cooperated with Ras in regulating cellular transformation (Nagakubo et al. 
1997; Cully et al. 2006). 
DJ-1 protein is formed of two monomers of 189 amino acids, (Nagakubo et al. 1997) and 
is ubiquitously expressed throughout the body. Alterations in DJ-1 levels or isoforms have 
been documented in brains (Bandopadhyay et al. 2004), cerebrospinal fluid (Herbert et al. 
2014) and plasma (Waragai et al. 2007) of sporadic PD patients, implying a role also in the 
common sporadic disease.  
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A lot of research effort was invested in the characterization of the DJ-1 neuronal putative 
role in cell protection against oxidative stress (Taira et al. 2004). Many studies focused on 
deciphering the role of Cys-106, a highly conserved residue (Girotto et al. 2014) as the 
activity of DJ-1 protein is mainly regulated by oxidation in this residue and in a lesser extent 
by the oxidation of C46 and C56 (Canet-Avilés et al. 2004; Kinumi et al. 2004; Meulener et 
al. 2005). This may be due to the reduced pKa value of Cys-106 (5.4) that confers a high 
reactive cysteine thiolate anion at physiological pH (Witt et al. 2008). Cys-106 also has a 
marked susceptibility to dopaquinone reactivity It has also been proved that oxidation of Cys-
106 has a different but most likely complementary role, which is its ability to drive and 
control DJ-1 mitochondrial localization. 
DJ-1 may regulate different cellular functions depending on its subcellular localization. 
It has been found to be present in the cytosol, nucleus and to a lesser degree the 
mitochondria. Upon exposure to growth factors and oxidation of the C106 residue, DJ-1 is 
translocated to the nucleus where it plays a pivotal role in the regulation of transcription, and 
specifically antioxidant gene regulation (Ariga et al. 2013).  
The role of DJ-1 in autophagy/mitophagy is poorly understood, although it is suggested 
that a decrease in mitochondrial membrane potential will result in the translocation of DJ-1 to 
the mitochondria, where mitophagy would be initiated through mechanisms that are still 
unknown (Krebiehl et al. 2010). 
DJ-1 has various other diverse biological implications such as its role in oncogenesis and 
male infertility (Kahle et al. 2009). Furthermore, it has been found to have chaperone and 
protease activity, enabling it to inhibit a-synuclein aggregation death (Shendelman et al. 
2004; Zhou and Freed 2005). It was recently discovered that DJ-1 is implicated in the 
protection of neurons from dopamine toxicity. By activating VMAT2 (which transfers 
dopamine as well as toxic dopamine by products into synaptic vesicles for its exocytotic 
release), DJ-1 can increase the resistance to dopamine toxicity and to decrease ROS levels in 
the cell (Lev et al. 2013). Furthermore, DJ-1 regulates the transcription of the tyrosine 
hydroxylase gene, key enzyme in dopamine synthesis pathway (Ishikawa et al. 2010). It is 
clear that this protein is critical for maintaining a healthy mitochondrial environment and 
reducing oxidative stress levels in the cell through major roles in transcriptional regulation 
and the elimination of ROS (van der Merwe et al. 2015). 
1.3.2.4 ATP13A 
In 2006, the group of Kubisch described for the first time the role of ATP13A2 in the 
Kufor-Rakeb syndrome (KRS), a hereditary rare form of early onset PD named after the 
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Jordanian district where the families involved in the first genetic linkage study lived. The 
KRS affected patients show juvenile onset PD, the youngest patient was reported as 12 years-
old Lithuanian boy (Park, Blair, and Sue 2015 ), with most of PD clinical symptoms 
including rigidity, bradykinesia, postural instability, and in some cases cognitive impairment 
and hallucinations (Park, Blair, and Sue 2015 ).  
ATP13A2 gene encodes a vacuolar/lysosomal P5B-ATPase of around 129 kDa with ten 
trans-membrane domains, predominantly expressed in the brain with high expression level 
reached in cortex, thalamus and SNc (Ramirez et al. 2006; Rinaldi et al. 2015). Moreover, 
ATP13A2 expression was found in dopaminergic neurons from both ventral tegmental area 
and SNc (Ramirez et al. 2006). The KRS associated mutations are caused by missense or 
deletion/insertion of few nucleotides that generate a frameshift that alters the transmembrane 
topology leading to a loss of function of the protein. Exception is made with mutation 
identified in a Chilean family that falls in an intronic region creating an alternative splicing 
site that excludes ATP13A2 exon 13 (Park, Blair, and Sue 2015; Ramirez et al. 2006)  
ATP13A2 protein is involved in different biological mechanisms ranging from Zn2+ 
homeostasis that insures correct mitochondrial function to alpha-synuclein lysosomal 
degradation and internalization in multivesicular bodies (Park, Blair, and Sue 2015; Usenovic 
et al. 2012; Kong et al. 2014). 
1.4 Take home messages 
1.4.1 PD related genes play a key role at the presynaptic site  
Accumulating pieces of evidence are pointing out how the genes involved in PD have a 
role in the regulation of the presynaptic activity. Increasing amount of studies associate α-
synuclein function to the regulation of exocytosis of neurotransmitter vesicle pools, depicting 
it as a chaperone for SNARE complexes protecting them from misfolding or non specific 
associations upon disassembly (reviewed in(Hunn et al. 2015)  
Combinatory knock out mice studies indicate that it acts on the same pathway as cysteine 
string protein-alpha (CSPa), a known SNARE chaperone. Moreover, the study of Garcia-
Reibock that used a transgenic mouse that expresses truncated human alpha synuclein (1-
120) developing alpha synuclein aggregates, reports that it presents also, age dependent 
redistribution of SNARE proteins and striatal DA release reduction that translates in reduced 
locomotion (Garcia-Reitböck et al. 2010). Reduced DA transmission and alteration in the 
distribution of synaptic vesicles was reported also in a study of the BAC transgenic mouse 
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that incorporates the human SNCA genomic locus with flanking regulatory elements (Janezic 
et al. 2013). Furthermore, alpha-synuclein knockout mouse showed an increased evoked DA 
release, suggesting alpha-synuclein as an activity-dependent negative regulator of dopamine 
(DA) neurotransmission (Abeliovich et al. 2000). Interestingly, also DJ-1 and PINK1 
knockout mice exhibit reduced DA overflow and impaired striatal synaptic plasticity (Kitada 
et al. 1998). Finally, severe neurotransmission defects have been repeatedly observed in 
different LRRK2 rodent models [reviewed in (Belluzzi, Greggio, and Piccoli 2012)]. Thus, 
presynaptic neurotransmitter release could arise as the first pathway compromised in PD and 
contribute to early stage symptoms of the disease. 
1.4.2 PD related genes play a key role in protein clearance  
Protein misfolding and aggregation have been instead suggested as the final trigger of the 
neurodegeneration occurring in the late phase of PD. The first indications are suggesting 
degradation impairment in neurons were the detection of protein inclusions in post-mortem 
specimen from PD patients [reviewed in (Cookson 2005)]. The protein inclusions in PD 
patients may be due to failure of the three major intracellular protein breakdown pathways, 
the i.e. ubiquitin-proteasome system (UPS), and autophagy and endosome-lysosome system. 
Protein clearance plays pivotal roles in maintaining the homeostasis of the nervous system: in 
fact, neurons are particularly prone to accumulate abnormal proteins as they do not 
regenerate, and proteasomal activity pronouncedly declines with aging. Basal autophagy is 
especially high in neuronal cells, and neurons undergo degeneration when basal autophagic 
degradation is disrupted (Cherra and Chu 2008). Autophagy failure seems to underlie a 
variety of neurodegenerative diseases (Chu 2006) and deregulation of autophagy is evident in 
the brains of PD patients (Janda et al. 2012). Among brain areas, the SN is particularly 
vulnerable because the oxidative metabolism of dopamine promotes free radical formation 
and protein misfolding. Furthermore, dopamine can interact with alpha-synuclein to promote 
the formation of toxic protofibrils and protein aggregation (Olanow and McNaught 2006). 
Further confirmation for the linkage between protein clearance and PD came from the 
observation that the systemic administration of proteasomal inhibitors causes Parkinson-like 
neuropathological changes, including the formation of Lewy-like inclusions in rodents 
(McNaught et al. 2002). The investigation of the familial form of PD brought the final 
confirmation to the connection between impaired protein clearance and PD. In fact, Parkin is 
an ubiquitin protein ligase (Goldberg et al. 2003) and alpha-synuclein protofilaments, but not 
oligomers, inhibit the catalytic activity of the 26S proteasome in vitro (Zhang, Tang, and Liu 
2008). Finally, mitochondrial autophagy was proved to be regulated by the PD genes Parkin, 
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PINK1 and DJ-1 (de Vries and Przedborski 2013). Mouse brains or primary neurons with 
deficiencies in Parkin, PINK1 and DJ-1, exhibit mitochondrial abnormalities that may be due 
to insufficient mitophagy [reviewed in (Giordano, Darley-Usmar, and Zhang 2014)]. 
2 LRRK2 
2.1 Insight on LRRK2 
Mutations in LRRK2 gene (PARK8; OMIM 609007) are linked to late-onset autosomal 
dominant Parkinson's disease, accounting for up to 13% of familial PD cases compatible with 
dominant inheritance and 1 to 2% of sporadic PD patients, thus suggesting this protein as the 
most significant player in PD pathogenesis identified to date. Several single nucleotide 
alterations have been identified in LRRK2 covering all functional domains, but only five 
missense mutations clearly segregate with PD in large family studies (Tong et al. 2012). 
Disease segregating mutations in LRRK2 have been reported in the kinase domain (G2019S, 
I2020T), the Roc domain (R1441C/G) and in the COR domain (Y1699C) [reviewed in (Mata 
et al. 2006)] 
 
Figure 2. Schematic structure of LRRK2 protein highlighting the most common PD related mutations sites.  
 The literature suggests that the G2019S mutation in the kinase domain increases LRRK2 
kinase activity, whereas mutations in the Roc domain appear to decrease the GTPase activity 
of LRRK2, to affect protein dimerization and may increase kinase activity [reviewed in 
(Moore 2008)]. The G2019S mutation has also been identified in Parkinsonism patients with 
no family history of the disease (Gilks et al. 2005) and accounts for up to 40% of sporadic 
parkinsonism in certain populations [reviewed in (Benamer and de Silva 2010)]. Clinically 
and pathologically, the features of LRRK2-associated parkinsonism are often 
indistinguishable from idiopathic PD [reviewed in (Whaley et al. 2006)]. Thus, this molecule 
has become one of the most attractive therapeutic targets for scientific investigation, 
intervention, and neuroprotection in parkinsonism. Although studies show little concordance 
regarding the level of LRRK2 mRNA/protein expression in the SN, LRRK2 protein 
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expression has been demonstrated in tyrosine-hydroxylase positive neurons of the SN pars 
compacta and in medium-sized spiny neurons of the striatum (Mandemakers et al. 2012). At 
the sub-cellular level, precedent studies showed that LRRK2 is mainly associated with 
mitochondria but also with multiple vesicles structure, including multivesicular bodies 
(Alegre-Abarrategui et al. 2009) and synaptic vesicles (Piccoli et al 2014). The LRRK2 
protein has a molecular weight of approximately 280 kDa and contains several domains 
including a Ras/GTPase-like (Roc), a C-terminal of Roc (COR), a kinase (similar to Mitogen-
activated protein kinase kinase kinases) and a WD40 domain (Anand and Braithwaite 2009). 
LRRK2 is a serine/threonine kinase with low endogenous tyrosine kinase activity(West et al. 
2005). In particular, LRRK2 preferentially phosphorylates threonine residues with the F/Y-x-
T-x-R/K sequence as the main phosphorylation consensus (Pungaliya et al. 2010). In vitro 
assays have suggested the nature of some LRRK2 substrates, including auto-phosphorylation, 
moesin, 4E-BP, MKKs, tubulin beta, alpha-synuclein and S15 ribosomal protein (Lobbestael, 
Baekelandt, and Taymans 2012). However despite its predominance in PD, the physiological 
function of LRRK2 and the meaning of such phosphorylations are not known and, therefore, 
the implication of LRRK2 and its kinase activity in the etiology of PD are far from being 
understood. 
2.2 LRRK2 influences synaptic activity 
Recent studies have provided strong evidence that LRRK2 impacts directly secretory and 
endocytic molecular machinery. Shin and colleagues (Shin et al. 2008) demonstrated that 
LRRK2 interacts with Rab5b, a regulator of endocytic vesicle trafficking. Xiong and 
colleagues showed that LRRK2 overexpression reduces the rates of synaptic vesicle 
endocytosis and exocytosis in hippocampal neurons (Xiong et al. 2010). Matta and 
colleagues proposed that LRRK2 regulates vesicle cycling via phosphorylation of Endophilin 
A (Mata et al. 2012). The molecular mechanisms underlying these synaptic transmission 
defects, however, remain largely elusive. Synaptic vesicles undergo in the nerve terminal to 
high-frequency trafficking cycles thanks to the presence of extremely specialized machinery, 
allowing very rapid triggering and switching off of synaptic vesicle exocytosis in response to 
depolarization-evoked calcium influx. The process is finely tuned and depends on the 
interaction between protein expressed on SV membranes and protein expressed on the 
presynaptic membranes (Rizo and Südhof 2012). This complex network of interaction is 
plastically shaped by post-translational modifications: the presynaptic modulation of 
neurotransmitter release is in fact altered by protein kinases and protein phosphatases 
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(Turner, Burgoyne, and Morgan 1999) by protein degradation (Ehlers 2003). As wild-type 
LRRK2 is characterized by a low kinase activity in absolute term, it might be argued that 
physiologically LRRK2 acts as a scaffold protein and its residual kinase activity is important 
to regulate monomer-dimer ratio (Sen, Webber, and West 2009). Instead, given the pre and 
postsynaptic alteration seen in the LRRK2 disease model, an attractive hypothesis is that 
mutant LRRK2 influences synaptic structure and function through gain-of-function effects on 
synaptic proteins. One possibility worth to be explored is that LRRK2 pathological kinase 
activity alters SV trafficking and thus synaptic function via modification of presynaptic 
proteins. Our hypothesis is that targets of pathological LRRK2 kinase activity might be 
hidden among LRRK2 interactors.  
It will be of critical interest to determine which regulatory proteins in the secretory, 
endocytic or autophagic pathways, if any, are LRRK2 kinase substrates to gain insight into 
the pathology. Strikingly, an increased dopamine turnover has been noticed in pre-
symptomatic LRRK2 mutation carriers (Sossi et al. 2010). Increased turnover might arise as a 
compensatory mechanism to counteract DA-neurons loss (Adams et al. 2005), but it has also 
been suggested that increased DA turnover might by itself contribute to the progression of 
disease secondary to DA associated toxicity (Zigmond, Hastings, and Perez 2002). The 
dysregulation of DA cycle might arise as one the first biological pathway compromised 
during PD onset and account for premotor symptoms happening in the preclinical stage of the 
disease.  
2.3 LRRK2 modulates protein clearance 
While a presynaptic impairment might indeed explain early stage or preclinical 
manifestation of PD, it is difficult to envisage how aberrant vesicle release could cause the 
neuronal loss in the substantia nigra reported in the late phase of the disease. Post-mortem 
brain investigation demonstrated that LRRK2G2019S kindred most often show 
synucleinopathy, occasionally tauopathy, suggesting a role for LRRK2 in protein inclusion 
pathology (Taymans and Cookson 2010). Recent studies showed that LRRK2 overexpression 
led to proteins accumulation without affecting the catalytic activity of the proteasome or 
expression levels of proteasomal core sub complexes (Lichtenberg et al. 2011; Skibinski et al. 
2014). Interestingly, a recent paper by Tong and collaborators shows that loss of LRRK2 
causes accumulation alpha-synuclein, increased autophagy and cell death in kidneys of aged 
mice (Tong et al. 2012). An impaired autophagic balance has been observed upon 
overexpression of LRRK2 in neuronal, non-neuronal and yeast cells (Gómez-Suaga et al. 
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2014). This comes in agreement with findings showing that a significant portion of 
endogenous LRRK2 is localized to membranous structures including endosomes, lysosomes, 
and phagosomes (Schapansky et al. 2014). Finally, experimental evidence suggests that 
LRRK2 kinase activity controls autophagy via the modulation of Ca2+ release from 
lysosomes in an mTOR-independent manner (Gómez-Suaga et al. 2014). All together, these 
data clearly suggest a tight implication of LRRK2 in the regulation of protein clearance via 
autophagy. Although alpha-synuclein is a major component of LB, immunohistochemical 
studies have shown that LB contains more than 90 molecules. Intriguingly, several proteins 
we have described as LRRK2 interactors (Piccoli et al. 2014, Piccoli et al. 2011) have been 
found in LB [i.e. AP-2, HSP-90, spectrin, clathrin heavy chain, CADPS, VPS-35 (Xia et al 
2008)] or in the related intranuclear inclusion body [i.e. NSF, dynamin, MUNC-18-1, Rab3A 
and HSP-90 (Pountney et al. 2008)]. There is a consensus that LRRK2 phosphorylates 
threonine residues flanked by positively charged residues such as lysines (Pungaliya et al. 
2010). Interestingly, lysine residues are the acceptor site for ubiquitination reaction. 
Ubiquitin chains tags on lysine residues are the major signal directing proteins towards 
degradation. Ubiquitinated proteins are cleared via either proteasome or autophagy. Also, the 
endosome-lysosome system is likewise regulated by ubiquitin [reviewed in (Luzio et al. 
2009).  
24 
 
2 Aims of study 
Mutations in the LRRK2 gene account for 1-2% of all PD cases and are associated with a 
form of dominantly inherited PD with clinical and pathological presentation similar to the 
sporadic syndrome. We have provided robust demonstration that LRRK2 acts at the 
presynaptic site. Moreover, our previous data suggest that LRRK2 binds and phosphorylates 
presynaptic targets and that G2019S mutation in LRRK2 associated with altered 
neurotransmitter release. Here we investigated whether G2019S mutation might affect 
presynaptic function in short term and substrate clearance in long term. Next, we evaluated 
the feasibility of two potential therapeutic strategies: the first implies the use of LRRK2 
kinase inhibitors while the second focuses on treatment ameliorating protein degradation via 
induction of autophagy. In order to address the goals outlined above, we achieved these 
objectives: 
 
1. LRRK2 G2019S pathological function at the synaptic site.  
We have identified the substrates of LRRK2 kinase activity and evaluated the functional 
outcome of these modifications, by studying the SV dynamics and neuronal morphology 
of cortical neuronal cultures derived from BAC human LRRK2 G2019S mouse.  
2. LRRK2 G2019S impact on substrate clearance  
We evaluated whether LRRK2 phosphorylation influences the ubiquitination of the 
substrates for LRRK2 kinase activity and we investigated the mechanism underlying such 
effect 
3. Pharmacological treatment to counteract LRRK2 G2019S dysfunctions 
We characterized a murine model of G2019S LRRK2 mutation in terms of protein 
clearance focusing on the characterization of a biochemical and motor phenotype of BAC 
human LRRK2 G2019S mouse model. Next we evaluated the feasibility of a treatment 
stimulating protein clearance in this animal model. 
 
25 
 
3 Materials and methods 
1 Animals 
Non-transgenic wild-type (WT) and BAC LRRK2 G2019S (GS) mice, back-crossed on a 
C57BL/6J strain, were a kind gift from Prof. M. Morari after agreement with Dr. Heather 
Melrose at MayoClinic (Jacksonville, FL, USA) (Melrose et al. 2010). Animals were kept 
following guidelines of Ministry of Education, Universities and Research (MIUR) in a 
normal light/dark cycle (12 hours light/ 12 hours dark) and had free access to food and water. 
2 Plasmids, lentiviral vector constructs and virus production 
pCHMWS 3xFlag-tagged LRRK2 wild-type, K1906M and G2019S, 2x-Myc LRRK2 
LRRK2 –GFP constructs have been previously described (Civiero et al. 2012)(Civiero et al 
2012)], NSF constructs (full-length and domains) were cloned into p3XFLAG-CMV-7.1 
vector (Sigma-Aldrich).  
NSF mutants were generated using the QuickChange mutagenesis kit (Agilent 
Technologies, CA, USA) according to the manufacturer's instructions. All plasmids were 
validated by restriction analysis and DNA sequencing. 
Myc ubiquitin and HA ubiquitin constructs were bought from Addgene.  
Lrrk2 silencing sequences were identified as presented in (Piccoli et al. 2011). The 
silencing sequence (5’-3’) for both human and murine Lrrk2 is mib3, 
AAGTTGATAGTCAGGCTGAAT while AGTGCTCCCGGTATCAGATG olig 6 sequence 
was used for the silencing of murine Lrrk2. The sequences were synthesized and cloned into 
green fluorescent protein (GFP)-expressing pLVTH as described in Bauer et al. 2008.  
The lentiviral viruses were produced by transient transfection of HEK293T cells 
according to standard protocols (Wiznerowicz and Trono 2003). 
3 Cell culture, transfection and drug treatments 
Neuron cultures were prepared from the mouse cortexes obtained from embryonic day 
15.5–16.5 Wild-type or GS mice (C57BL/6J). Briefly, after brain dissection the cortexes 
were mechanically dissociated after 15 min incubation with 2,5% Trypsin (Euroclone) at 37 
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°C in agitation. The resulting cells were counted and plated on previously poly-D-lysine 
(Sigma) treated wells or cover slips, according to the desired density.  High density (750–
1000 cells/mm2) and medium-density (150–200 cells/mm2) neuron cultures were plated and 
grown on 12-well plastic tissue culture plates (Iwaki; Bibby Sterilin Staffordshire, UK) or 
12mm diameter cover slips put into 24-well plastic tissue culture plates (Iwaki) at 37°C and 
5% CO2 (Piccoli et al., 2007). Neuronal transfection was carried out using Lipofectamine 
2000 (Life Technologies) following the manufacture’s instruction. The cells were treated 
with LRRK2 kinase inhibitor, GSK-2578215A (Tocris Bioscience, Bristol, UK), MG132 
(Tocris Bioscience, Bristol, UK) and Trehalose (Sigma) by addition to culture media at the 
concentrations indicated through the text. 
Human embryonic kidney cells (HEK293T) were cultured in DMEM complete: 
Dulbecco's modified Eagle's medium (DMEM, Euroclone) supplemented with 10% fetal 
bovine serum (FBS, Euroclone) at 37°C and 5% CO2. HEK293T were transiently transfected 
using linear polyethylenimine (PEI, Polysciences) with ratio DNA: PEI 0.8:100. 4 µg of 
DNA were dissolved in 0.5 ml of PEI solution and vortexed for 20 sec. Then, the DNA-PEI 
mix was incubated for 10 minutes at room temperature (RT).  Finally, the solution was added 
directly to the cells in Petri dishes of 10 cm2 and used after 48-72 hours. 
4 Antibodies, SDS-PAGE and western blot analysis 
Antibodies used for Western blotting were as follows: anti-Flag M2 (Sigma-Aldrich), 
anti-NSF (Cell Signaling), anti-LRRK2 (MJFF2, Abcam), anti-actin (Sigma), anti-Myc 
(Millipore), anti-HA (Millipore). Between 10 and 20 µg of protein samples were resolved on 
to 10-15% Tris-glycine polyacrylamide gels in SDS/Tris-glycine running buffer. Precision 
plus molecular weight marker (Biorad) were used for size estimation. Solubilized proteins 
were then transferred to nitrocellulose or polyvinylidenedifluoride (PVDF) membranes in 
blotting buffer containing 10% methanol. The membranes were blocked in 5% nonfat dry 
milk in Tris-buffered saline and 0.1% Triton (TBS-T) for 1 hour at RT and then incubated 
overnight at 4°C with primary antibody in blocking solution. The sheets were washed in 
TBS-T (3x10 min) at RT followed by incubation for 1 h at RT with horseradish peroxidase-
conjugated anti-mouse/rat/rabbit IgGs. Blots were then washed in TBS-T (3x10 min) at RT, 
and immunoreactive proteins were visualized using enhanced chemiluminescence plus 
(ECL+, GE Healthcare, Little Chalfont, England). Densitometric analysis was carried out 
using Image J software. 
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5 SypHy assay 
Cortical cultures were generated from E16.5 embryos from Wild-type and GS mice as 
previously described. At DIV3 primary neurons were infected with viruses expressing sypHy, 
a fusion construct of synaptophysin and super ecliptic pHluorin (Granseth et al. 2009). 
Neurons were chronically treated with 0.2um GSK or DMSO every two days starting at DIV 
0. SypHy positive boutons were assayed in a stimulation chamber on the stage of an Applied 
Precision Delta Vision RT microscope. The assay was carried out as described previously 
(Sankaranarayanan & Ryan 2000). Briefly, cells were submerged in 200µl of KRH Buffer 
(25mM HEPES, 130mM NaCl, 5mM KCl, 6mM D-glucose, 1.3mM MgSO4, 1.2mM 
KH2PO4, 2mM CaCl2, pH 7.4) plus 25µM CNQX and 50µM APV inhibitors of AMPA and 
NMDA receptors. SypHy was excited at 475 nm and its fluorescence emission collected at 
525 nm using a 60X, oil immersion objective. Images were acquired every second for 200 
seconds using TillVision software (TILL Photonics). At frame 30, cells were stimulated with 
40 action potential (AP) (20Hz) then at frame 70 with 300 AP (20 Hz). Total fluorescence 
was measured upon incubation with 50mM NH4Cl. Quantitative measurements of the 
fluorescence intensity at individual boutons were obtained by averaging a selected area of 
pixel intensities using ImageJ. Net fluorescence changes (ΔF) were obtained by subtracting 
the average intensity of the first 15 frames (F0) from the intensity of each frame (Ft) for 
individual boutons and normalized F0 (ΔF/F0). The fluorescence increase and decay, reflect 
exo- and endocytosis, respectively [28]. Both the fluorescence upstroke and decay were fitted 
with a single exponential τ (τupstroke and τdecay respectively). Data are expressed as mean ± 
SEM and statistical significance were assessed by unpaired two-tailed Student’s t-test 
(GraphPad Prism). 
6 Exo-endo 
At DIV 14 Wild-type or GS cortical neuronal cultures were incubated for 5 min at 37°C 
with rabbit anti-synaptotagmin 1 (SynapticSystem) 1:400 in DMEM (Euroclone). The cells 
were then washed for 3x with PBS 1X and fixed with 4% paraformaldehyde, 4% sucrose in 
PBS. The antibody used in this initial phase, recognizes the intravesicular domain of 
synaptotagmin 1 that is exposed to the neuronal membrane after the vesicles exocytosis, 
marking the recycling synaptic vesicles (SV). After fixation and permeabilization, a 
synaptophysin counterstaining with mouse anti-synaptophysin, 1:400 (Sigma-Aldrich) 
visualized the totality of SV. Acquired images were processed and quantitatively analyzed 
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with ImageJ software using the analyse particles function to automatically count 
synaptophysin positive clusters and synaptophysin positive clusters present in the region of 
interest. 
7 Morphology analysis  
Wild-type and GS cortical neurons plated on 12mm diameter cover spills treated with 
poly-D-lysine at a medium-low density (111-150 cells/mm2) were transduced at DIV 3 with 
mib3 (human and murine LRRK2 shRNA), olig 6 murine LRRK2 shRNA and c1 scramble 
shRNA for control using a viral MOI (Multiplicity of Infection) of 3.  The cells were 
chronically treated with LRRK2 inhibitor GSK as previously described, and fixed at DIV 14 
with 4% paraformaldehyde, 4% sucrose in PBS. Images were acquired using an Axioplan 
Zeis Epifluorescence microscope and the neurites were tracked using NeuronJ. 
8 Immunocytochemistry  
DIV 14 GS and Wild-type neurons previously treated or transfected were fixed for 10 
min at RT with 4% para-formaldehyde, 4% sucrose pH 7.4. Fixed cells were washed three 
times with PBS 1X for 10 min, and then incubated over night at 4oC with primary antibody 
diluted in GDB 1X (0.1% gelatin, 0.1% Triton X 100, 450mM NaCl). We used as primary 
antibodies: mouse anti-NSF (SySy 1:500) and rabbit anti-caspase 3 clivated (Life 
Technologies 1: 200). After 3 washes with High Salt solution (NaCl 500mM, NaPO4 20mM) 
10 min each, the coverslips were incubated for 1 hour at RT with the secondary antibodies 
anti-rabbit Alexa 630 (1:500), anti-mouse Alexa 555 (1:500) and Dapi 1:2000 in GDB 1X. 
Then they were washed three times in High Salt solution, 10 min each and once in PBS. After 
washing thoroughly with PBS, coverslips were rinsed in distilled water and mounted on glass 
slides with MOVIOL. The mounted coverslips were kept at 4°C until observation under with 
laser scanning confocal microscope Zeiss LSM 510. 
9 Proteasome activity assay 
 Proteasome activity of GS and Wild-type brain tissue was analysed following the 20S 
Proteasome activity assay kit protocol Millipore (APT280). The assay is based on the 
detection of the fluorophore 7-Amino-4-methylcoumarin (AMC) after cleavage from the 
labeled substrate LLVY-AMC. The free AMC fluorescence is quantified using a 380/460 nm 
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filter set in a fluorometer. Briefly, 3µg of protein from each sample was incubated for 1 h at 
37°C with proteasome labeled substrate in 96 dark multiwells. In parallel we test the 
sensibility of the assay performing a dilution series of proteasome positive control (1:4 to 
1:256) by diluting the stock solution in 1X Assay buffer.  Fluorescence data was collected 
using a PE Biosystems CytoFluor 400 plate reader using a 380 nm excitation and 460nm 
emission filters.    
10 Tube 
12 or 6 months old GS and Wild-type mice whole brains were lysed my mechanical 
homogenization in 5ml glass potters followed by 1 h incubation at 4°C in rotation in 5 ml of 
lysis buffer (50mM HEPES pH 7.4, 150mM NaCl, 1% Triton X-100, 0.5mM EDTA, 
protease inhibitors (Calbiochem) and phosphatase inhibitor cocktails II and IV (Calbiochem). 
The samples were centrifuged for 15 min at 15000xg at 4°C and the surnatant was recovered. 
The amount of protein was determined by interpolation to a Bradford-BSA standard curve. 1 
mg of protein from each sample was incubated for 2h at 4°C in rotation with the previously 
equilibrated Agarose TUBE resin in 50mM HEPES pH 7.4, 150mM NaCl. Then the agarose 
beads were washed in 50mM HEPES pH 7.4, 150mM NaCl, 1% Triton X-100, 0,2% Triton 
X-100, and the ubiquitinated proteins bound to the resin were eluted in 60µl of Laemil buffer 
1X after 10 min incubation at 52°C.  The immunoprecipitated proteins were analysed through 
SDS-PAGE and western blot as previously described. 
11 Immunoprecipitation 
HEK293T cells were transiently transfected for 48 hours with LRRK2 G2019S–GFP, 
NSF WT–N-terminal Strep-Flag and Myc-ubiquitin and treated for 24 hours with 10 µM 
MG132 with or without 2 µM LRRK2 kinase inhibitor IN-1. The cells were resuspended in 
5ml ice cold PBS 1X, centrifuged at 150xg for 5 min and lysed in 1 ml of 50mM HEPES pH 
7.4, 150mM NaCl, 0.5mM EDTA, 0.5% Triton X-100, protease inhibitors (Calbiochem) and 
phosphatase inhibitor cocktails II and IV (Calbiochem), after incubation for 1 h at 4°C in 
rotation. The cell lysate was recovered after 10 min centrifugation at 15000xg at 4°C and 
10% of supernatant was kept as input. The remaining supernatant was incubated with 50 µl of 
strep resin (50% ethanol) for 1 hour at 4°C in rotation. The beads were then washed 3X with 
0.5 ml of 50mM HEPES pH 7.4, 150mM NaCl, 0,2% Triton X-100 and NSF bound was 
eluted in three elution steps in Biotin elution buffer. 
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The eluted NSF was next incubated with 30 µl of FLAG M2 resin (Sigma) for 1 hour at 
4°C in rotation. 
The resin was then washed 3X with 0.5 ml of 50mM HEPES pH 7.4, 150mM NaCl, 
0,2% Triton X-100, and the protein eluted in 60µl of Laemil buffer 1X after 10 min 
incubation at 52°C. The immunoprecipitated proteins were analysed through SDS-PAGE and 
western blot as previously described. 
12 Protein purification 
Human NSF with a N-terminal Strep-Flag tag and human LRRK2 G2019S with a 3X 
Flag tag were purified from HEK293T cells after transient transfection as following. Cells 
were resuspended in 1 ml of a Lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM 
EDTA, 2.5mM Na4P2O7, 1mM beta-glycerophosphate, 1mM Na3VO4, Protease Inhibitor 
Mixture (Sigma-Aldrich)) and then lysed with 5 cycles of freezing and thawing in liquid 
nitrogen. The cell lysate was collected after centrifugation at 15000xg for 40 minutes at 4°C. 
The supernatant was incubated overnight with 40µl of Anti-Flag M2 Affinity gel (Sigma-
Aldrich) at 4°C in rotation. After 1 min centrifugation at 2000xg, the supernatant was 
discarded and the beads with human NSF or LRRK2 G2019S were washed with 1 ml of 
different buffers. For NSF the washing buffers is Tris-HCl pH 7.5, 150mM NaCl used for 
four times while for LRRK2 G2019S the washing buffers are: WB1 (20mM Tris-HCl pH 7.5, 
500mM NaCl, 1% Triton X-100) twice, WB2 (20mM Tris-HCl pH 7.5, 300mM NaCl, 1% 
Triton X-100) twice, WB3 (20mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100) twice, 
WB4 (20mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% Triton X-100) twice, WB5 (20mM Tris-
HCl pH 7.5, 150mM NaCl, 0.02% Triton X-100). The proteins were eluted by incubating the 
beads with 100 µl of 20mM Tris- HCl pH 7.5, 150mM NaCl with 150 ng/µl Flag peptide for 
NSF and 3xFlag peptide for LRRK2G2019S at 4°C in agitation for 30 min. The sample was 
centrifuged to pellet the resin, and the supernatant was collected. The elution step was 
repeated and the resulting elutions combined at a final volume of 200 µl. Purified proteins 
were separated on SDS-PAGE and quantified by comparison with different concentrations of 
BSA (Bovine Serum Albumin). Proteins were electrophoretically resolved on 10% Tris-
glycine polyacrylamide gels (Biorad) using SDS/Tris-glycine running buffer. To estimate the 
molecular weight of proteins Precision Plus molecular weight marker (Biorad) was used. 
After the run, proteins were stained with Coomassie Brillant Blue to enable the quantification 
with ImageJ software. 
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13 Kinase assay 
NFS and LRRK2 G2019S purified human proteins at a ratio of 2:1, were incubated in 
25mM 25mM Tris-HCl pH 7.5, 5mM beta-glycerophosphate, 2mM DTT, 0,1mM Na3VO4, 
10mM MgCl2, 5mM ATP for 3 hours at 30°C in agitation. The reaction was stopped by 
adding 600µl of ubiquitination buffer (40mM HEPES, pH 74, 40mM NaCl, 5mM MgCl2 plus 
protease and phosphatase inhibitor cocktails Calbiochem).  
14 In vitro ubiquitination 
In order to eliminate LRRK2 G2019S protein from the kinase assay reaction product 
dissolved in 600 µl of ubiquitination buffer (40mM HEPES, pH 74, 40mM NaCl, 5mM 
MgCl2 plus protease and phosphatase inhibitor cocktails Calbiochem), the phosphorylated 
NSF protein was bound to Strep resin beads after 2 hours incubation with 50µl of Strep resin 
previously equilibrated in 500µl of ubiquitination buffer. The beads were washed 3 times 
with 500 µl ubiquitination washing buffer (40mM HEPES, pH 74, 40mM NaCl, 5mM MgCl2 
, 0,2% Triton X-100) and divided for the incubation with the in vitro ubiquitination reaction 
mix (1 µg of Myc-Ubiquitin transfected or control not transfected HEK cells lysate diluted in 
40mM HEPES, pH 74, 40mM NaCl, 5mM MgCl2 , plus 5mM ATP,  0.1mM MG132,  
0.2mM PR-619) for 30 min at 37°C at 700 rpm. The reaction was stopped by a short 
centrifugation at 2000xg and removal of the supernatant. The beads were washed once with 1 
ml of UB 1x, and the ubiquitinated NSF bound was eluted in 60µl of Laemil buffer 1X after 
10 min incubation at 52°C. 
15 Filter assay 
DIV 14 high-density GS and Wild-type cortical neurons treated for 24 h with 100mM 
Trehalose (Sigma) and controls, were rinsed once in cold PBS 1X and mechanically detached 
in PBS 1 X plus protease and phosphatase inhibitor cocktails Calbiochem (40 µl/well 12 
wells plate). Every two wells were pulled together and sonicated 3x with 1s pulse and 1s stop 
sequence at 10% pulse amplitude. The protein quantity was determined by interpolation at a 
BSA standard curve, and 10 µg of each sample were diluted to 120 µl pre-loading volume in 
PBS 1X. Through a dot blot void system, the samples were exposed to a previously methanol 
equilibrated cellulose acetate membrane that keeps on its surface the protein aggregates. The 
membrane was saturated for 1 h at RT in 5% nonfat dry milk in Tris-buffered saline and 
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0.1% Triton (TBS-T) and then incubated with the primary antibody mouse anti-NSF (SySY) 
(1:1000) or mouse anti Rab3A (SySY) 1:1000 in saturating solution for 90 min at RT. The 
unbound primary antibody was sheets was washed out in TBS-T (3x10 min) at RT and the 
membrane was incubated for 1 h at RT with horseradish peroxidase-conjugated anti-mouse 
IgGs. After 3 washes in TBS-T 10 min/each at RT, the immunoreactive proteins were 
visualized using enhanced chemiluminescence plus (ECL+, GE Healthcare, Little Chalfont, 
England). Densitometric analysis was carried out using Image J software. 
16 Immunohistochemestry 
6 and 12 months old Wild-type and GS mice were anesthetized with avertine and 
transcardially perfused with PBS followed by 4% paraformaldehyde in PBS. Brains were 
dissected, postfixed for 2 h in 4% paraformaldehyde at 4°C, and then placed into a 30% 
sucrose solution in PBS for 24 h. Brains were sectioned coronally on a Leica microtome with 
cut thickness of 30 µm. Free floating brain sections were quenched for 15 min in TBS 1X 
plus 3% H2O2, 10% methanol at RT, then washed three times with TBS 1X. Sequently the 
slices were saturated in TBS 1X plus 3% BSA, 10% NGS, 0,1% Triton X-100 for 90 min in 
agitation at RT and incubated with the primary antibody (mouse anti-NSF 1:1000 ) O/N at 
4°C in agitation. Next, the sections were washed 2 times /10 min each, in TBS 1X – 0.1% 
Triton X-100 and incubated for 30 min with the blocking solution TBS 1X  plus 3% BSA, 
10% NGS, 0,1% Triton X-100 and for 2 hours with the secondary antibody anti-mouse HRP 
1:200 at RT in agitation. The slices were incubated for 1 h with Vectastain ABC kit 1:1 mix 
(Vectorlab), washed 3 times in TBS 1X – 0.1% Triton X-100 and developed with DAB 
quanto mix (Thermo Scientific) for 30 sec. The stained sections were rinsed in TBS 1X, 
dehydrated and mounted using DPC mounting reagent (Sigma) and kept at RT until 
acquisition with a Zeiss Axio Imager m2m.  
For immunofluorescence, the blocked sections were incubated with the primary antibody 
as previously described, followed by incubation with Cy3-conjugated goat anti-mouse (1:500 
Life Technologies), and mounted on poly-lys coversplips using the Calbiochem mounting 
reagent. The stained sections were kept at 4°C until acquisition with Zeiss Axio Imager m2m. 
17 Trehalose treatment  
At 4 or 10 months, Wild-type and GS male littermates were divided into Trehalose and 
control groups. In the Trehalose group, mice were treated daily for 2 months with 1% 
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Trehalose drinking water solution. The treatment solution was changed every week. In the 
control group, mice were given untreated drinking water.  Mice body weight was measured 
every week since the start of treatment. 
18 Behavior 
18.1 Spontaneous motor activity  
Motor function was evaluated in an activity cage (43 × 43 × 32 cm) (Ugo Basile, Varese, 
Italy), placed in a sound attenuating room, as previously described (Sala et al. 2011). The 
cage was fitted with two parallel horizontal and vertical infrared beams located 2 cm and 4 
from the floor, respectively. Before the start of the test each mouse was habituated to the 
testing room for 1 h. Cumulative horizontal and vertical movement counts were recorded 
every 10 min for 180 min. 
18.2 Balance Beam walking 
The beam apparatus consists of 1-meter beams with a flat surface of 12mm or 6mm 
width resting 50 cm above the tabletop on two poles. A black box is placed at the end of the 
beam as the finish point. Nesting material from home cages is placed in the black box to 
attract the mouse to the finish point. A lamp (with 60 watt light bulb) is used to shine light 
above the start point and serves as an aversive stimulus. A video camera is set on a tripod to 
record the performance. On training days, each mouse crosses the 12mm beam 3 times and 
then the 6mm beam 3 times. The time required to cross to the escape box at the other end (80 
cm away) is measured a stopwatch. The stopwatch is started by the nose of the mouse 
entering the center 80 cm, and stopped when the animal reaches the end of the 80 cm. Once 
the mice are in the safe box, they are allowed some time (~15 secs) to rest there before the 
next trial The mice rest for 10 min in their home cages between training sessions on the two 
beams.  On the test day, times to cross each beam are recorded. Two successful trials in 
which the mouse did not stall on the beam are averaged. The beams and box are cleaned of 
mouse droppings and wiped with towels soaked with 70% ethanol and then water before the 
next beam is placed on the apparatus. 
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18.3 Pole test 
In the vertical pole task, the mouse was placed on a vertical wire-mesh pole with its head 
facing upwards. Mice were habituated to the task in 2 trials per day for 2 days. On test day 
(third day) mice were subjected to 5 trials: the total time taken to turn the body and to 
descend was recorded according to Hickey et al. (2008). A cut-off of 60sec was given. Data 
were shown as mean of 5 trials evaluated during the test day. 
18.4 Hanging wire test 
Each mouse was placed on a wire cage lid and the lid was gently moved back and forth 
so as to enable the mouse to grip the wire according to Glynn et al. (2005). The lid was then 
turned upside down about 15 cm above the surface of the bedding material. Latency to fall 
onto the bedding was recorded with a cut-off of 180 sec.  
18.5 Rotarod 
The rotarod apparatus (Ugo Basile, Biological Research Apparatus, Varese, Italy) was 
used to measure fore and hindlimb motor coordination and balance. During the training 
period, each mouse was placed on the rotarod at a constant speed (12 or 32 rpm) for a 
maximum of 120sec, and the latency to fall off the rotarod within this time period was 
recorded. Mice received four trials per day for 4 consecutive days. The fourth trial of each 
day was evaluated for statistical analysis. 
18.6 Novel Object recognition (NOR) 
Object recognition was conducted over a two-day period in an open plastic arena (38cm 
× 30cm × 18cm) (Fig. 1). The apparatus was illuminated by a fluorescent lamp placed 
centrally above it (75W). The animals were first habituated to the test apparatus for 10 min 
on day 1 and then subjected to a familiarization trial (T1) and a novel object recognition trial 
(T2) on day 2. In NOR, real objects were used. They consisted of white plastic cylinders and 
coloured plastic Lego stacks of different shapes. Each mouse was placed in the centre of the 
arena between the two objects for a maximum of 20 min or until it had completed 30 s of 
cumulative object exploration. Object recognition was scored when the animal was within 0.5 
cm of a object with its nose towards the object. Exploration was defined as follows: directing 
the nose to the object and/or touching the object with the nose. Sitting on, or leaning to, an 
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object was not considered to be an exploratory behavior.  Care was taken to minimize the 
difference between the to-be discriminated objects in order to prevent a greater preference for 
one of the two objects. An experimenter blind to the treatment group manually recorded the 
exploration times to the objects in each animal. Mice that did not explore any of the two 
objects for at least 30 s during T1 were excluded from the data analysis. During T2 each 
mouse was placed again in the same arena (retention session) in which one of the two 
identical familiar object was replaced with a novel one. 
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4 Results 
1 LRRK2 G2019S mutation influences SV trafficking  
Previous work of our group demonstrated that LRRK2 controls synaptic transmission 
acting as a presynaptic scaffold (Piccoli et al. 2011; Piccoli et al. 2014) and that inhibition of 
LRRK2 kinase activity impairs SVs trafficking, indicating a role for LRRK2 catalytic activity 
in SV fusion cycle (Cirnaru et al. 2014). Our recent data further depicts the role of LRRK2 
kinase activity at the presynapse. We have recently identified the presynaptic ATPase NSF as 
a substrate of LRRK2 kinase activity, which once phosphorylated displays enhanced ATP 
hydrolysis and SNARE complex dissociation activity in vitro (Belluzzi et al. 2015; 
appendix). These effects disappeared when we mutated the threonine 645 in the ATP binding 
pocket of D2 domain of NSF with an alanine, indicating this residue as bona fide LRRK2 
phosphorylation site on NSF. Moreover, we confirmed the role of LRRK2 kinase activity in 
SV recycling. All together, these data arose the need to analyze the impact of LRRK2 
G2019S, pathologic hyperactive kinase mutation, at the presynaptic site. For this purpose, we 
analyzed the dynamics of SV fusion through sypHy assay in the primary cortical culture 
obtained from BAC hLRRK2 G2019S (GS), and wild-type E18 mice chronically treated with 
0.2µM GSK or DMSO as control.  SypHy is a pH-sensitive fluorescent reporter that, by 
analogy with the original synaptopHluorin (synaptobrevin-pHluorin, (Sankaranarayanan et al. 
2000; Miesenböck, De Angelis, and Rothman 1998) is quenched in the acidic intracellular 
space of the SV and will only become fluorescent upon SV fusion, when the contents of the 
SV is exposed to the more basic pH of the extracellular space.  As shown in figure 3 B, at the 
onset of the stimulus, exocytosis caused a rapid increase in sypHy fluorescence, which after 
cessation of the stimulus, through endocytosis, slowly returned to baseline (Fig.3 A-B). The 
first stimulus, 40 AP, is predicted to mobilize SV belonging to the ready releasable pool 
while 300 AP are sufficient to trigger the fusion of SV belonging to the total recycling pool. 
We measured a significant increase of fluorescence in GS neurons impaired to the wild-type 
upon either 40 or 300 AP stimuli (Figure 3 C), that is cancelled upon GSK treatment (Fig 4). 
These results confirmed our expectation that hyperactive LRRK2 kinase activity influence 
SV fusion. Nonetheless, we wanted to exclude a dysregulation in the functioning of vacuolar 
H+ATPase responsible for the acidification of the endocytic vesicles (Inoue et al. 2005; 
Morel and Poëa-Guyon 2015). For this, we analyzed the effect of LRRK2 G2019S mutation 
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on the presynaptic SV recycling by exposing living GS and wild-type DIV 14 neuronal 
cultures to rabbit polyclonal antibody directed against the intraluminal vesicular NH2 
terminus domain of synaptotagmin 1 (Matteoli et al. 1992). Upon endocytosis, the antibody is 
trapped inside the vesicle lumen, marking the recycling vesicle. To track the neuronal 
processes, the cells were infected at DIV 4 with control GFP-expressing virus. The cycling 
vesicles appear as clusters positive for synaptotagmin 1 and synaptophysin. In agreement 
with the results obtained with the sypHy assay, we observed a significant increase of 
synatptagmin positive clusters in GS neurons compared to the Wild-type (Fig.5) Interestingly 
the chronic treatment with GSK significantly reduced the amount of synaptotagmin positive 
clusters. Nonetheless, in this case, the treatment had no effect on the SV recycling in the 
Wild-type neurons. This might be due to the difference of the events detected by the two 
assays: synchronous neurotransmitter release trigger by action potential in the case of the 
sypHy assay and spontaneous exocytotic events in the last one characterized by different 
regulation in SNARE complex formation (Ramirez et al. 2006). 
  
Figure 3.  (A) Synaptophluorin fluorencesce was recordered from DIV 14 wild-type and BAC hLRRK2 G2019S (BAC 
hG2019S) cortical neurons. Representative snapshots were taken from 1Hz recordings at rest (0), after 40 action potential 
stimulation (40AP), after 300 action potential stimulation (300AP) and upon neutralization with 50mM NH4Cl, F (max). (B) 
The graph shows rappresentative pattern of fluorescence. The Y-axis reports the ΔF/F0 at the given time point (second). (C)  
the graphs report the increase in the fluorescence after 40 AP (ΔF40/F0) and 300 AP (ΔF300/F0) and the kinetic signal after 
300AP expressed as time constant describing the increase (tau uspstroke) and decay (tau decay) of fluorescence. Data are 
expressed as mean ± SEM, n=4, at least 50 boutons from minimum 6 neurons were analyzed per experiment. 
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Figure 4. (A) Synaptophluorin fluorencesce was recordered from DIV 14 wild-type and BAC hLRRK2 G2019S (BAC 
hG2019S) cortical neurons chronically treated with LRRK2 kinase inhibitor GSK 0.2µM or DMSO as control.  
Representative snapshots were taken from 1Hz recordings at rest (0), after 40 action potential stimulation (40AP), after 300 
action potential stimulation (300AP) and upon neutralization with 50mM NH4Cl, F (max). (B) The graph shows 
rappresentative pattern of fluorescence. The Y-axis reports the ΔF/F0 at the given time point (second). (C)  the graphs report 
the increase in the fluorescence after 40 AP (ΔF40/F0) and 300 AP (ΔF300/F0) and the kinetic signal after 300AP expressed 
as time constant describing the increase (tau uspstroke) and decay (tau decay) of fluorescence. Data are expressed as mean ± 
SEM, n=4, at least 50 boutons from minimum 6 neurons were analyzed per experiment. 
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Figure 5. The exo/endocytotic assay was performed at DIV 14 on wild-type and BAC hLRRK2 G2019S cortical neurons, 
chronically treated with LRRK2 kinase inhibitor GSK 0.2 µM, trasduced at DIV 4 with control virus expressing GFP. 
Cycling SV appears as synaptotagmin (s-tagmin) positive cluster along neuron processes. The total vesicular pool was 
marked by incubation with anti-synaptophysin antibodies upon fixation and permeabilization. Images show signals for 
synaptotagmin and synaptophysin merged with the GFP channel. The graph indicated the ratio of synaptotagmin and 
synaptophysin positive clusters on the synaptophysin positive ones, that indicates SV recycling rate. Data are expressed as 
mean ± SEM, n=4, minimum 7 neurons were analyzed per experiment.  
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2 LRRK2 protein levels and kinase activity influence neuronal 
morphology  
LRRK2 hG2019S BAC mouse overexpress the human mutated in G2019S LRRK2 protein 
together with the murine wild-type LRRK2 protein. The human transgenic protein expression 
resembles endogenous mLRRK2, being more expressed in the hippocampus (Melrose et al. 2010). 
Deficits in neurite outgrowth of LRRK2 hG2019S BAC mouse cultured neurons have been 
thoroughly described in a consistent amount of studies (Winner et al. 2011; Kawakami et al. 2012; 
Dachsel et al. 2011) but none dissects the specific contribution to the impaired phenotype of LRRK2 
kinase activity versus the increase in protein level. Wanting to fill this gap, we analysed the 
morphology of BAC hLRRK2 G2019S and wild-type cortical neurons in different experimental 
conditions. We modulated the murine LRRK2 gene expression by using a virus which expresses a 
miRNA sequence that specifically silences murine LRRK2 (olig 6) and human and murine 
expression by is using a virus that express a miRNA sequence that silences both murine and human 
LRRK2 protein (mib3). Both of these viruses co-express GFP protein that allows the investigation of 
neuronal morphology. We verified the selective silencing of murine and human LRRK2 in primary 
mice neurons and in HEK293T cells overexpressing hLRRK2 by western blot (Fig 6). 
 
Figure 6. (A) mib3 and olig6 LRRK2 silencing efficiency was tested in wild-type cortical neurons infected at DIV 4 and 
lysed at DIV 14. 15 µg of protein from each sample were resolved in SDS-PAGE and the expression of LRRK2 investigated 
by incubation with LRRK2 specific antibody. The total amount of protein was normalized using β tubulin signal. The graph 
indicates the levels of expression of LRRK2 in control condition (C8), olig 6, mib3 ***p<0.001 T-test. (B) mib3 and olig6 
LRRK2 silencing efficiency was tested HEK293T cells by co-trasfection with human LRRK2 wild type construct. The graph 
indicates the levels of LRRK2 expression in untrasfected, trasfected with LRRK2 wild type, LRRK2 wild and mib3, LRRK2 
wild type and olig6 ***p<0.001 T-test. 
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 In order to characterize the morphological phenotype of the GS neurons versus wild-
type ones, cortical neuronal cultures were infected at DIV 4 with control viruses expressing 
GFP. Neurons were processed for imaging purposes at DIV14. Interestingly we noticed that 
GS neurons were characterized by a significant reduced complexity of the neurite tree, as 
judged by the measurement of total neurite length. To understand which is the impact of 
LRRK2 kinase activity on the morphological phenotype, the infected cultures were 
chronically treated with 0.2µM GSK or DMSO as control starting from DIV0 to DIV14. The 
analysis revealed a partial recovery of the neurite outgrowth (Fig 7 GS C1 Ct and GS C1 
GSK lanes). Wanting to analyse the specific impact of LRRK2 G2019S mutation and protein 
levels on the morphology we infected the GS and wild-type neuronal cultures with viruses 
expressing murine LRRK2 silencing vector (olig 6) and performed the chronic treatment with 
GSK LRRK2 kinase inhibitor as previously described.  Surprisingly we observed that murine 
LRRK2 silencing induced a partial recovery of the phenotype similar to the one induced by 
the inhibition of LRRK2 kinase activity. Moreover, murine LRRK2 silencing combined with 
the inhibition of LRRK2 kinase activity lead to a full recovery of the neurite tree in LRRK2 
G2019S. We asked next which was the role of LRRK2 protein in the neurite outgrowth so we 
infected the GS and wild-type neuronal cultures at DIV4 with both human and murine 
LRRK2 silencing vector (mib3) and analysed their morphology upon chronic treatment with 
GSK. Strikingly we observed that the overall LRRK2 silencing induced an increase in the 
neurite tree of the GS neurons compared to the wild-type ones.   
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Figure 7.  The total number of neurites was analyzed in DIV 14 wild-type and BAC hLRRK2 G2019S cortical neurons 
chronically treated with LRRK2 kinase inhibitor GSK 0.2µM or DMSO as control. The neurons were infected at DIV 4 with 
C1 control virus, olig 6 murine LRRK2 silencing virus or mib3 human and murine LRRK2 silencing virus. Neurites were 
tracked using Neuron J plugin. The graph indicates the number of neurites in each condition indicating the contribution of 
LRRK2 overexpression (OE) or kinase hyperactivity (G2019) to the phenotype. Data are expressed as mean ± SEM, n=4, a 
minimum 15 neurons were analyzed per experiment. 
As previously reported, we observed a significant reduction in neurite number and length 
in the GS neurons compared to wild-type. This difference was reduced upon chronic LRRK2 
kinase inhibition. Surprisingly, murine LRRK2 silencing produced the same effect suggesting 
that both kinase activity and LRRK2 protein levels mediate this effect (GS olg6 condition). 
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Nonetheless, the selective murine LRRK2 silencing via Olig 6 in GS was also associated to a 
reduction in neuronal complexity, indicating the contribution of LRRK2 G2019S mutation to 
the phenotype. Strikingly, inhibition of LRRK2 kinase activity in olig 6 infected neurons, by 
GSK treatment, reverts the morphologic phenotype to a Wild-type level, while the silencing 
of both murine and human LRRK2 via mib3 (comparable to a KO model) generates an 
increase in neuronal complexity. These results indicate the importance of both LRRK2 
protein levels and kinase activity in the regulation of neuronal morphology outlining the 
importance of LRRK2 in a fine-tuning regulation mechanism that impacts the neuronal 
morphology. 
All together these data demonstrate the usefulness of BAC hG2019S model: in fact, the 
over-expression of human LRRK2 protein and the increased kinase activity cause a similar 
phenotype in terms of neurite tree complexity reduction. 
3 G2019S neurons suffer proteasome inhibition 
The ubiquitin-proteasome system (UPS) is one of the pathways involved in the control of 
a correct protein turnover and clearance of misfolded proteins, regulating protein 
concentration accordingly to the cell cycle phases. The function of UPS is often linked to the 
development of neurodegenerative disease where damaged proteins tend to accumulate and 
generate toxic aggregates that alter the normal cellular function. Alteration of the UPS was 
observed in both sporadic and hereditary PD (Olanow and McNaught 2006; McNaught et al. 
2002) and its different enzymatic activity deeply analyzed. In particular, LB were reported in 
the basal ganglia of LRRK2 G2019S patients Thus, we assessed UPS functionality in brain 
lysate obtained from GS and Wild-type 12-months old mice by using a fluorimetric assay that 
detects the fluorophore 7-Amino-4-methylcoumarin (AMC) after cleavage from the labeled 
substrate LLVY-AMC. Proteolytic activity resulted similar in GS, and Wild-type samples 
(Fig 8 A) and the relative activity values fell within the range expected for physiological 
proteasome activity (Fig 8 B). 
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Figure 8. (A) 20 S proteasome activity was measured in brain lysate obtained from 12 months old BAC hLRRK2 G2019S 
and wild-type mice., by fluorimetric detection of the fluorophore 7-Amino-4-methylcoumarin (AMC) (B) Standard curve of 
proteasome positive control. 
Next we asked whether GS neurons might have different susceptibility to blockage of 
UPS activity. Thus we exposed wild-type and GS neurons to sub-optimal acute proteasome 
inhibition.  
To this aim, we treated cortical cultures with 75nM MG132 for 24 hours. Next, neurons 
were processed for immunofluorescence analysis and stained for cleaved caspase 3 (CC-3), a 
reporter of cell death. Interestingly we found that GS neuron suffer more for proteasome 
inhibition, respect to the wild-type ones (Fig 9).  
0 20 40 60 80
0
50000
100000
150000
200000
µl  Proteasome Positive control 
R
FU
0
2000
4000
6000
8000
10000
12000
14000
wild.type G2019S	
RF
U
A B
45 
 
 
Figure 9.  The susceptibility to proteasome inhibition was tested in DIV 14 wild-type and BAC hLRRK2 G2019S cortical 
neurons by treatment with 75nM MG-132 proteasome inhibitor for 24 hours. The neurons were infected at DIV 4 with 
control virus expressing GFP stained after fixation with 4% paraformaldehyde, for cleaved caspase 3, that marks the 
apoptotic cells and NSF. The image presents the neuronal morphology stained by the GFP, the signal of NSF in red channel 
and of CC-3 in blue. The graph indicates the mean intensity levels of total fluorescence for NSF (Upper panel) and CC-3 
(lower panel).  Data are expressed as mean ± SEM, n=4, a minimum 10 neurons were analyzed per experiment.  
4 NSF accumulates in PD patient and co-aggregates with alpha 
synuclein in LB. 
It is commonly accepted that alpha-synuclein is the main constituent of the LB, but 
recent studies reveals the presence of other proteins including LRRK2 (Alegre-Abarrategui et 
al. 2009). Moreover, the work of Pountney et al, reports the presence in the LB related 
intranuclear inclusion bodies of NSF, Munc18-1 and dynamin 1(Pountney et al. 2008), 
recently identified LRRK2 interactors (Piccoli et al 2014). Considering that NSF is not only 
an interactor but also of substrate of LRRK2 kinase activity that modifies its ATPase activity 
upon phosphorylation, leading to an alteration in the SV dynamics, we asked whether there is 
a pathologic connection among the presence of LRRK2 G2019S and the distribution of NSF 
in G2019S PD patients basal ganglia. For this, we performed immunofluorescence analysis 
on basal ganglia sections of G2019S LRRK2 patient (Fig 10) and we observed that NSF can 
be found in large aggregates. Moreover, NSF aggregates co-localize with alpha synuclein. 
This evidence suggests that NSF precipitates in structures resembling LB. 
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Figure 10. The presence of NSF aggregates and their co-localization with alpha synuclein was tested in basal ganglia of 
G2019S PD patient by staining with NSF antibody (Synaptic System) and alpha synuclein (Cell Signaling).   
5 LRRK2 G2019S mutation correlates with deposition of NSF 
aggregates 
Wanting to deepen the understanding of NSF accumulation in the PD G2019S patients 
we further investigate the levels and distribution of NSF taking advantage of the GS mice. 
We performed immunohistochemistry analysis of NSF distribution in coronary 30um free 
floating slices of 12 months old GS and wild-type mouse brain. As expected, we observed 
that NSF antibody decorates perinuclear aggregates in the striatum of 12 months old G2019S 
mice (Fig 11A). 
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Figure 11. (A) The presence of NSF aggregates in the striatul of 12 months old wild-type and BAC hLRRK2 G2019S was 
evaluated by staining of 30 µm coronal free floating brain coronal slices with anti-NSF antibody. The image presents a 
normal cytosolic distributed signal in the wild-type sample and a perinuclear aggregated signal in the BAC hLRRK2 
G2019S one. (B) Filter retention assay performed on sonicated wild-type and BAC hLRRK2 G2019S cortical neurons 
reveals aggregation of NSF in the G2019S sample. (C) Graph presents the quantification of filter assay optical density of 
NSF signal on the wild-type (WT) and BAC hLRRK2 G2019S (GS). Data are expressed as mean ± SEM, n=4.  
In order to further characterize NSF aggregation we performed a filter assay on GS and 
wild-type cultured neurons at DIV 14. This assay is able to identify the soluble but 
aggregated protein species as well as insoluble ones by retaining them on a cellulose acetate 
membrane (Rusmini et al. 2013). We report a significant increase in NSF aggregation in GS 
sample compared to the wild-type (Fig 11B).  
6 LRRK2 G2019S kinase activity impairs NSF ubiquitination 
There is a general consensus that LRRK2 phosphorylates threonine residues flanked by 
positively charged residues such as lysines (36) acceptor site for the ubiquitination of target 
proteins, and that the G2019S mutation induces a 2 fold increase in LRRK2 kinase activity. 
Considering our recent data that report NSF as one of LRRK2 interactors and substrate 
(Belluzzi et al.2015 appendix), we hypothesized that NSF phosphorylation by LRRK2 
wild-type G2019S
striatal slice from 12-months old mice, 100X 
A
**	p<0.01	t-test
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G2019S mutation might induce an alteration of its clearance. Thus we asked whether NSF 
aggregation in both neuronal cultures and tissue obtained GS mice might arise from an 
altered ubiquitination. To this aim we used the TUBE resin that is able to bind any 
ubiquitinated protein, to isolate ubiquitinated proteins. To test the potentiality of our strategy 
we first assayed neuronal culture treated or not with MG132. Upon TUBE enrichment, 
proteins were eluted in Laemmli buffer and analysed by immunoblotting. Interestingly we 
noticed an increased yield of NSF purification upon MG-132 treatment. These data suggest 
that 1) NSF can be ubiquitinated, 2) TUBE assay enriches in ubiquitinated proteins. Next we 
assayed by TUBE protein samples extracted from midbrain of wild-type and G2091s animals 
sacrificed at 6 and 10 months. By western-blotting, we detected a reduced amount of 
ubiquitinated NSF in G2019S mice sacrificed at the age of 10 months. 
 
Figure 12. NSF ubiquitination levels were analysed by immunoprecipitatin of the ubiquitinated proteins  using the Tandem 
Ubiquitin Binding Elements (TUBE) resin from 10 month old wild-type and BAC hLRRK2 G2019S (TG) midbrain lysate. 
Proteins were eluted and analysed by western-blotting with anti-NSF specific antibody. (B) Graph shows NSF yield upon 
TUBE purification in 10 months old mice. Data are expressed as mean ± SEM, n=4. 
7 LRRK2 impairs NSF ubiquitination in vitro 
Thus, we asked whether LRRK2 phosphorylation might alter NSF ubiquitination. To this 
aim, we investigated the pattern of ubiquitination of NSF upon LRRK2 phosphorylation. We 
tested three NSF construct; wt, phosphodeficient T645A and phospho competent T646A. 
Recombinant Strep-FLAG-NSF wild-type or FLAG-NSF T645A or FLAG-NSF T646A were 
co-trasfected with GFP-LRRK2 G2019S, and Myc-Ubiquitin in HEK293T cells. One day 
before cell lysis, cells were treated with the UPS inhibitor MG- 132 (10 µM) in combination 
or not with the LRRK2 kinase inhibitor IN-1 (2µM). After solubilisation, NSF proteins were 
Input& TUBE&
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70 kDa 
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purified with a double immunoprecipitation protocol on Streptavidin resin followed by 
FLAG-M2 resin and eluted in Laemmli buffer. Eluates were separated on SDS- PAGE and 
the yield of NSF-ubiquitination was investigated by immunoblotting with anti-Myc 
antibodies. Interestingly, we noticed that the pattern of NSF ubiquitination was significantly 
increased in sample purified from cells expressing NSF and LRRK2 G2019S upon with IN-
1(Fig 13). Moreover, in the sample expressing NSF T645A that cannot be phosphorylated by 
LRRK2, NSF ubiquitination pattern does not change after the treatment with IN-1, 
suggesting that the alteration in the ubiquitination level of NSF is dependent of NSF 
phosphorylation by LRRK2.  
 
Figure 13. The impact of LRRK2 kinase activity on NSF ubiquitination was evaluated by double immunoprecipitation of 
NSF WT–Strep-Flag (WT) and phosphoresistant NSF T645A- Strep-Flag protein, overexpressed in HEK293T cells in 
presence of LRRK2 G2019S and Myc-ubiquitin. The cells were treated for 24 hours with 10µM MG132 and LRRK2 
inhibitor 1 IN-1 or DMSO as control. The proteins were eluted in Laemmli buffer and analysed by western-blotting. The 
iimunoprecipitation of NSF was verified with anti-Flag antibody while the ubiquitination of the immunoprecipitates was 
verified by incubation with anti- Myc antibody. The graph indicated the variation of ubiquitination signal of NSF (WT) and 
NSF T645A in presence of LRRK2 IN-1 calculated the ratio of the ubiquitination signal from IN-1 treated samples (+) and 
control (-). Data are expressed as mean ± SEM, n=5 **p< 0.001, T-test. 
To further explore the link between LRRK2 phosphorylation and NSF ubiquitination, we 
took advantage of a kinase-dead variant of LRRK2, LRRK2 K1906M. This artificial variant 
has undetectable kinase activity (Civiero et al. 2012) We purified NSF from culture 
expressing FLAG-NSF, myc-LRRK2 K1906M, and HA-Ubiquitin treated with MG-132 or 
MG- 132 + IN-1. Anti-HA immunoblotting revealed that in this experimental setting, IN-1 
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does not modify NSF ubiquitination level (Fig. 14). Finally, to exclude off-side effect due to 
unspecific binding of IN-1 to NSF, we studied the ubiquitination patter of NSF purified from 
cells expressing NSF or GFP, treated or not with IN-1. We noticed that in the absence of 
LRRK2 co-expression, IN-1 does not influence NSF ubiquitination (Fig 14). Altogether these 
data indicate that NSF ubiquitination is specifically impaired upon LRRK2 phosphorylation.  
 
Figure 14. The specificity of LRRK2 kinase activity on NSF ubiquitination was analyzed by immunoprecipitation of NSF 
wild-type –Strep protein overexpressed in HEK 293T cells in presence of LRRK2 K1906M (kinase dead) and HA ubiquitin 
(upper panel) or GFP protein used as control (lower panel). The cells were treated for 24 hours with 10µM MG132 and 
LRRK2 inhibitor 1 IN-1 or DMSO as control. The proteins were eluted in Laemmli buffer and analysed by western-blotting. 
The immunoprecipitation of NSF was verified with anti- Flag antibody while the ubiquitination of the immunoprecipitates 
was verified by incubation with anti HA antibody. The graphs indicated the ratio of ubiquitination of the immunoprecipitate 
calculated the ratio of the ubiquitination signal and flag signal from IN-1 treated samples (+) and control (-). 
Next we asked whether LRRK2 kinase activity negatively affects overall UPS efficiency 
or instead specifically impairs NSF ubiquitination. To solve this issue, we exploited a cell-
free ubiquitination assay. Briefly, we purified NSF and LRRK2 from cell expressing 
respectively Strep-FLAG-NSF or FLAG LRRK G2019S. Purified NSF and LRRK2 were 
combined 1:2 in kinase permissive condition in the presence or not of IN-1 2µM. 
Subsequently NSF was isolated on streptavidin resin and then incubated with lysate obtained 
from cell over-expressing Myc-ubiquitin. The incubation was performed in a dedicated buffer 
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allowing ubiquitination (Antrobus and Borner 2011). Reactions were stopped after 30 minutes 
and proteins were resolved on SDS-PAGE. Ubiquitination level was evaluated by anti-Myc 
immunoblotting. Interestingly, we observed that NSF ubiquitination patter was reduced upon 
LRRK2 phosphorylation and that the treatment with IN-1 restored the ubiquitination levels to the 
ones of NSF exposed to the ubiquitination reaction without the presence of LRRK2.  
 
Figure 15. In vitro ubiquitination assay. Strep- FLAG NSF and 3X-FLAG LRRK2 proteins were purified from HEK293 
cells upon 48 hours transfection on FLAG-beads. NSF and LRRK2 purified proteins were incubated in a ratio of 1:2 in 
presence of 10mM ATP at 37°C to promote NSF phosphorylation by LRRK2. The impact on NSF ubiquitination of LRRK2 
kinase activity or presence of the LRRK2 protein was tested by running the phosphorylation reaction also in presence of IN-
1 10µM or in absence of LRRK2. The phosphorylated NSF was then trapped on Strep beads and incubated with 20 mg of 
Myc-ubiquin expressing HEK lysate (MYC ubq) or not transfected HEK lysate (HEK NT) donors of ubiquitin-proteasome 
substrates in the in vitro ubiquitination mix and 10mM ATP. The proteasome activity was inhibited by adding 10µM MG-
132 to the in vitro ubiquitination reaction. After 30 min, we stopped the reaction in Laemmli Buffer. We resolved the protein 
on SDS-PAGE. As shown by the blots we evaluated the immunoprecipitation (IP) and ubiquitination of NSF yield (IVU) via 
western-blotting with anti-Flg and anti-Myc antibodies. The graph indicates the ubiquitination signal of immunoprecipitated 
NSF in presence of kinase inhibited LRRK2 (IVU NSF GS In-1 MYC), active LRRK2 (IVU NSF GS MYC) and in absence 
of LRRK2 protein (IVU NSF MYC).  Data are expressed as mean ± SEM, n=5 **p< 0.001, T-test.  
These data confirm that NSF ubiquitination is regulated by LRRK2 and that LRRK2 
kinase activity directly controls it. 
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8 Reduced NSF clearance is toxic for G2019S neurons  
Protein aggregation is thought as one of the main cause of cytotoxicity that lead to the 
neuronal death in most of neurodegenerative diseases. For this, we asked whether NSF 
accumulation induces similar effects and, in case, if such effect depends on LRRK2 kinase 
activity. To answer this question, we analyzed the morphology of GS and Wild-type cortical 
neurons overexpressing FLAG-NSF- wild-type or FLAG-NSF T645A together with GFP. 
The neurites were tracked automatically using the GFP signal by Neuron Studio software. 
The reduction of neurites number is a marker of neuronal toxicity (Piccoli et al 2014). We 
confirm our previous observation of impaired neurite outgrowth in the GS neurons respect to 
the wild-type ones but we report that the overexpression of wild-type NSF is toxic for the GS 
neurons as the numbers of neurites is significantly reduced compared to the GS neurons 
transfected only with GFP (Fig 16 NT lane). Moreover the overexpression of NSF in wild-
type neurons does not induce any significant alteration in the total neurite number, thus does 
wild type neurons does not overt NSF toxicity.  
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Figure 16. NSF induced toxity was tested in wild-type and BAC hG2019S cortical neurons. The neurons were transfected at 
DIV 4 with GFP alone, FLAG-NSF wild-type plus GFP, FLAG-NSF T645A plus GFP and imaged at DIV 14 post staining 
with NSF specific antibody. The neurites were tracked automatically using the GFP signal by Neuron Studio software. The 
graph shows the total neurite number of wild-type neurons transfected with GFP (WT NT), NSF wild type - GFP (WT NSF 
WT), NSF T654A –GFP (WT NSF T645A) and BAC hG2019S (GS) neurons transfected with GFP (GS NT), NSF wild type 
- GFP (GS NSF WT), NSF T654A –GFP (GS NSF T645A). Data are expressed as mean ± SEM, n=3 **p< 0.001, T-test.  
Moreover, when we overexpressed in GS neurons, NSF T645A, resistant to LRRK2 
phosphorylation, we did report a significant recovery of neurite tree. This evidence suggests 
that the cytotoxic effect is dependent on NSF phosphorylation by LRRK2. All together these 
results suggest that NSF over-expression is toxic for GS neurons and that this effect is 
dependent on LRRK2 kinase activity. 
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9 Trehalose reduces NSF aggregates and ameliorates motor 
phenotype in BAC hG2019S mice 
Protein deposition can be attenuated by autophagy induction. Trehalose is a disaccharide 
that prevents aggregation of denatured proteins inducing their degradation via autophagy 
(Sarkar et al. 2007) and has been used successfully in reducing protein aggregation in a 
rodent model of Parkin-PD (Rodríguez-Navarro et al. 2010).  
Aged match wild-type and G2019S mice were offered water or water with 1% trehalose 
for 2 months. At the end of the treatment, we studied NSF deposition by 
immunohistochemistry striatal specimen from wild-type and G2019S 12-months mice treated 
or not with trehalose. Interestingly we noticed that in the GS trehalose-treated samples, NSF 
aggregates disappear, and NSF distribution is comparable to the wild-type. (Fig 17).  
 
Figure 17. Presence of NSF aggregates was analyzed in the striatum of 12 months old wild and BAC hLRRK2 G2019S 
mice treated for 2 months with aqueous solution of 1% Trehalose or water as control. Images show the staining with NSF 
specific antibody on 30µm free floating coronal sections revealed by DAB.   
Next we investigated the impact of LRRK2 mutation on motor and cognitive 
performances in 6 and 12 months old GS and wild-type mice. Motor coordination was 
evaluated by means of balance beam, pole and rotarod resistance test, while the episodic 
memory was analyzed by novel object recognition test. Specifically balance beam test on 6 
and 12 months of age wild –type and GS mice, was performed on 12mm beam and on 6mm 
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beam (fig.18). When the 6 months mice performed the test on 12mm beam, Two way Anova 
revealed a significant difference among the two genotypes (F(1,48) =5.61, P=0.02) but not 
for genotype (F(1,48)=0.47, P=0.49) and treatment (F(1,48) =0.16, P=0.68). Post hoc analysis 
revealed a significant difference between GS mice and their littermates only when treated 
with vehicle. Also when 6 months mice were tested on 6mm beam, Two way Anova revealed 
a significant difference among the two genotypes (F(1,48) =5.45, P=0.02) but not for 
genotype (F(1,48)=0.33, P=0.56) and treatment (F(1,48) =0.24, P=0.62). Bonferroni test 
revealed that GS mice took longer time to cross the beam compared to wild-type; when 
treated with trehalose, GS mice spent less time compared to their GS littermates treated with 
vehicle. This result indicates a partial recovery of the motor impairment of GS mice 
following the trehalose treatment. When tested in Balance Beam test at the age of 12 months 
(fig 18), Two way Anova did not revealed any significant differences among wild-type and 
GS mice although it indicates a significant difference among the wild-type treated or not with 
trehalose treatment (F(1,53) =4.63, P=0.03). Post hoc analysis revealed a significant decrease 
in time spent by wild-type treated with trehalose to cross the beam compared to their wild-
type littermates treated with vehicle. Finally, when tested at the age of 12 months on 12mm 
beam, two way Anova did not reveal any significant differences (genotype: (F(1,53) =0.62, 
P=0.43; treatment: (F(1,53) =0.42, P=0.51; genotype x treatment interaction: (F(1,53) =0.46, 
P=0.49). 
 
Figure 18. Motor coordination analyses evaluated by balance beam test of 6 and 12 months old wild-type and BAC 
hLRRK2 G2019S treated for 2 months with 1% Trehalose aqueous solution (TRH) or water (VEH). 
The Fig 19 shows the results of Pole test. At 6 months, Two way Anova, revealed a 
significant difference among GS and wild-type mice (F(1,45) =14.27, P=0.0005) but none for 
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the genotype and treatment interaction (F(1,45) =0.67, P=0.41). Post hoc analysis revealed a 
significant increase of the time request by GS mice treated with vehicle to complete the test, 
compared to corresponding wild-type mice. At 12 months, Two way Anova did not showed a 
significant difference among the genotype, nonetheless Bonferroni test revealed that GS 
mice, treated with trehalose, took longer time to complete the task compared to wild-type 
with the same treatment. 
 
Figure 19. Episodic memory analyses of 6 and 12 months old wild-type and BAC hLRRK2 G2019S treated for 2 months 
with 1% Trehalose aqueous solution (TRH) or water (VEH). 
In Fig 20 the Rotarod 32 rpm results are shown. At the age of 6 months, Two way 
Anova, revealed a significant difference of treatment as between subject factor (F(3,172) =8.71, 
P<0.0001), of time (F(3,172)=4.11, P=0.007) but not time x treatment interaction (F(3,172) =0.67, 
P<0.0001). Post hoc analysis revealed a significant decrease of time in vehicle treated GS 
mice at all tested trials while trehalose treatment significantly rescued the performance of GS 
mice. At 12 months, Two way Anova, revealed a significant difference of treatment as 
between subject factor (F(3,96) =18.22, P<0.0001), of time (F(3,96)=5.61, P=0.001) but not time 
x treatment interaction (F(9,96) =1.71, P=0.001). Post hoc analysis revealed a significant 
improvement of performance, after treatment, in GS mice only at the 2° and 3° trial. 
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Figure 20. Motor coordination analyses evaluated by rotarod 32 rpm of 6 and 12 months old wild-type and BAC hLRRK2 
G2019S treated for 2 months with 1% Trehalose aqueous solution (TRH) or water (VEH). 
When tested in the Novel Object Recognition test (Fig 21), at the age of 6 months, Two 
way Anova revealed a significant difference of treatment as between subject factor (F(3,129) 
=14.47, P<0.0001), but not of time (F(2,129)=0.26, P=0.76) and of time x treatment interaction 
(F(6,129) =1.05, P=0.39). Post hoc analysis revealed a significant reduction of index in vehicle 
GS mice at all the tested intervals compared to corresponding wild-type; trehalose treatment 
rescued at all the tested times but significantly only at 120 min. At age of 12 months similar 
pattern was shown [two way anova: treatment as between subject factor (F(3,120) =20.35, 
P<0.0001), but not of time (F(2,120)=1.08, P=0.34) and of time x treatment interaction (F(6,120) 
=0.72, P=0.63)]. Post hoc analysis revealed a significant reduction of index in vehicle TG 
mice at all the tested intervals compared to corresponding wild-type; trehalose treatment 
significantly rescued at all the tested times. 
 
Figure 21. Episodic memory analyses of 6 and 12 months old wild-type and BAC hLRRK2 G2019S treated for 2 months 
with 1% Trehalose aqueous solution (TRH) or water (VEH). 
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Summarizing, the results of rotarod at 32 rpm evidentiate a motor impairment of GS 
mice both at 6 and 12 months compared to wild type ones, whereas the balance beam and 
pole test results depicts a motor coordination of the GS mice already at 6 months of age. 
These motor deficits were rescued by the treatment with trehalose indicating a crutial role of 
the protein aggregation in the development of the motor defects. Moreover, we report also a 
cognivite impairment of the GS mice at both 6 and 12 months that is completely rescued by 
the trehalose treatment. 
Hence, this evidence suggests that autophagy induction via trehalose might protect from 
the NSF aggregation and motor and cognitive impairment observed in G2019S animals. 
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5 Discussion 
 Despite being responsible for most of the case of familial PD, the physiological function 
of LRRK2 is far from being understood. In this study, we focused on the role of LRRK2 
kinase activity. In particular, we characterized the impact of LRRK2 G2019S mutation on SV 
dynamics and neuronal morphology, and on NSF clearance. 
Accumulating evidence has pointed out how LRRK2 plays a role in the regulation of 
presynaptic activity. Severe neurotransmission defects have been observed in different 
LRRK2 models (Y. Li et al. 2009; X. Li et al. 2010; Tong et al. 2012). The R1441C LRRK2 
homozygous knock-in mice and the R1441C LRRK2 BAC (bacterial artificial chromosome) 
transgenic mice display impairments in nigrostriatal dopaminergic innervation and 
degeneration of the nigrostriatal projections (X. Li et al. 2010; Tong et al. 2009). 
Interestingly, the G2019S BAC transgenic mice show deficiencies in striatal dopamine 
release and increased striatal tau immunoreactivity without dopaminergic neuron loss in the 
SNpc (X. Li et al. 2010; Melrose et al. 2010). Previous studies of our group suggested that 
the presence of LRRK2 is mandatory or the proper neuronal electrophysiological activity, 
vesicular trafficking and spatial distribution of the presynaptic pool. We identified LRRK2 as 
a molecular hub, connecting synaptic vesicles to cytoskeletal elements via a complex panel of 
protein-protein interactions and described how the pharmacological inhibition of LRRK2 
kinase activity alters synaptic function (Piccoli et al 2014, Cirnaru et al 2014). Many studies 
report that LRRK2 might regulate SV dynamics by phosphorylation of presynaptic proteins 
such as endophilin and snapin  (Matta et al. 2012; Yun et al. 2013). Recently we have 
identified NSF as LRRK2 interactor and substrate. NSF phosphorylation on threonine 645, an 
important site for NSF oligomerization, increases NSF ATPase activity and increases the 
disassembly rate of SNARE complexes. It is important to mention that wild-type LRRK2 has 
a reduced kinase activity and that the gain of function conferred by the mutation G2019S 
might perturb proper neurotransmitter release. Indeed, our present data report a fast 
endocytosis in the LRRK2 hG2019S BAC cortical neurons, which is in line with the increase 
in the glutamate release that has been reported in LRRK2 G2019S knock-in mice. 
nonetheless our observation is in contrast with the reduced dopamine release observed in the 
G2019S BAC mice. This might be due to different regulation in the release of the 
dopaminergic dense core vesicles with respect to the glutamate one. For this we believe 
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further analysis of the DA synapse must be done using dopaminergic neurons, as we believe 
that the alteration of the intracellular trafficking might depict the starting point in the PD 
pathogenesis. Nonetheless the quantity of dopamine released depends also on the number of 
releasing sites available. As recently reported, SNc dopaminergic neurons have a massive and 
highly-tortuous axonal arborisation along which more 200 000 synapse are distributed 
towards the striatum (Matsuda et al. 2009; Hunn et al. 2015) . Decrease in the neurite tree 
complexity directly lead to reduce of the number of releasing sites and consequentially in 
quantity of neurotransmitter. In this study, we report the impact of both LRRK2 protein 
levels and kinase activity on the neuronal morphology of LRRK2 BAC hG2019S mice 
cortical culture neurons, indicating how the two act in the same direction generating a 
cumulative negative effect in the neurites outgrowth. Interestingly, chronic pharmacological 
inhibition of the kinase activity produced the same effects as the removal of the endogenous 
murine LRRK2 (olig 6 condition), highlighting also the specific contribution of LRRK2 
increase activity to the phenotype that remained impaired respect to the Wt. This was further 
proved by rescue noticed in the olig 6 condition, which is similar to a knock-in LRRK2 
hG2019S, upon chronic treatment with LRRK2 kinase inhibitor. Altogether, these data 
indicate that LRRK2 protein as well as its kinase activity controls the neurites outgrowth. 
Speculating on the observation of the study of Stewart et al. that report pronounced 
overgrowth of the neuromuscular junction of Drosophila that express a dominant negative 
genetically modified NSF, NSF2 (NSFE/Q) that is still able to bind MgATP but it hydrolysis 
ATP less (Stewart et al. 2002; Nunes et al. 2006) we are tempted to think that the reduced 
complexity of the neurite tree of the G2019S mice neurons might be mediated by a hyper-
phosphorylated NSF that hydrolysis more ATP. Moreover, we believe that through these 
observation we could explain the reduce in the dopamine release observed in the BAC 
G2019S mice, revealing two distinct mechanism that can lead to the early development of 
PD: alteration in SV dynamics and reduction of complexity of the neuronal processes. 
Nonetheless, further investigation is needed using a more appropriate disease model, such as 
the patient derived neuronal precursors that can be efficiently differentiate to dopaminergic 
neurons (Reinhardt et al. 2013). 
On the other hand, our data show that LRRK2 kinase activity might contribute also to a 
late pathological mechanism via impaired NSF protein clearance. We identified NSF 
aggregates that co-localize with alpha synuclein in the basal ganglia of LRRK2 G2019S PD 
patients as well as in the striatum of aged mice that over express hLRRK2 G2019S variant. 
These observations are in line with other post-mortem brain investigations that have shown 
that LRRK2 G2019S kindred most often show synucleinopathy, occasionally tauopathy, 
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suggesting a role for LRRK2 in protein inclusion pathology (Taymans and Cookson 2010). 
Recent studies showed that LRRK2 overexpression led to proteins accumulation without 
affecting the catalytic activity of the proteasome or expression levels of proteasomal core sub 
complexes (Lichtenberg et al. 2011). Indeed, our results indicate that the proteasome activity 
of the aged GS mouse is similar to the Wild-type ones. Thus, LRRK2 might control protein 
fate acting upstream of the proteasome, in particular influencing their ubiquitination. We 
reported here that LRRK2 G2019S aberrant kinase activity negatively correlates with NSF 
ubiquitination and subsequent degradation via proteasome. In particular, our data suggest that 
LRRK2 kinase activity directly impair ubiquitination of NSF rather than interfere with the 
proteasomal degradation system. As previously discussed, LRRK2 specifically 
phosphorylates NSF on Thr645 a site that is crucial for NSF oligomerization and catalytic 
activity (Belluzzi et al. 2015 appendix). Our hypothesis is that LRRK2 phosphorylation of 
NSF on the threonin 645 residue might impair via steric hindrance the addition of ubiquitin 
tagging on flanking lysine, impairing NSF ubiquitination. In fact, it will be of great interest to 
perform structural studies and analyse whether the phosphorylstion of this site may disturb 
via steric or elettric hyndrance the transfer of a ubiquitin chain to near-by lysine residue. 
Considering that wild-type LRRK2 has a low kinase activity, and that the protein bears 
multiple domains that mediate protein-protein interaction it is possible that the main function 
of LRRK2 is as a scaffolding protein with the residual kinase activity, important to regulate 
omophylic binding (Berger, Smith, and Lavoie 2010; Greggio et al. 2008). This might 
suggest that only upon mutation LRRK2 gains the capability of phosphorylating other 
proteins. In particular, despite the low stoichiometry characterizing LRRK2 G2019S 
enzymatic activity, we argue that LRRK2 phosphorylation of NSF might shift the equilibrium 
between ubiquitinated and not ubiquitinated NSF. This event might impair NSF clearance via 
proteasome and eventually induce its cytosolic aggregation. The proper turnover of NSF is 
crucial for the correct functioning of the presynaptic processes as NSF is a key component of 
presynaptic machinery, allowing the first step of SV recycling (Pallanck et al. 1995). 
Numerous studies have shown that depletion of cytosolic NSF impair membrane fusion 
machinery (Rothman 1994) and results in accumulation of intracellular vesicles (Malhotra et 
al. 1988; Mohtashami et al. 2001). Interestingly, experimental ischemia induces NSF 
aggregation into Triton-X 100 insoluble inclusions that sequester synaptic vesicle (Liu and 
Hu 2004)(Liu and Hu, 2004). Therefore, NSF aggregation might affect the presynaptic fusion 
machinery, determining a reduction of the neurotransmitter exocytosis that might explain the 
early stage or preclinical manifestation of PD in animal model (Melrose et al. 2010) or in 
LRRK2 G2019S carriers (Sossi et al. 2010). Protein clearance plays an important role in the 
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homeostasis of the neuronal cells, particular sensitive to abnormal proteins accumulation as 
they do not regenerate and lose the proteasomal activity with aging. Thus, impairment in NSF 
clearance might explain also the neuronal loss in the substantia nigra reported in late phase of 
the disease. Indeed, our experimental data suggests that NSF accumulation in cytoplasmic 
aggregates is toxic. Moreover, we report that NSF aggregation cytotoxicity is dependent on 
LRRK2 kinase activity. Altogether, this evidence could leave space for a therapeutic strategy 
targeting LRRK2 kinase activity. Several brain penetrant LRRK2 selective inhibitors have 
been identified (Deng et al. 2011; Reith et al. 2012; Sheng et al. 2012); however, the wide 
expression of LRRK2 in other organs apart from the central nervous system, including lung, 
kidney and the immune system raised issues about side effects. Last but not least, our recent 
data describing a functional role of endogenous LRRK2 enzymatic activity at the synaptic 
site (Cirnaru et al. 2014) and the severe kidney abnormality reported upon chronic inhibition 
(Herzig et al. 2011) reduce the feasibility of pharmacological strategy targeting LRRK2 
kinase activity. The pharmacological modulation of protein clearance is instead an achievable 
goal: the degradation of protein misfolding can be improved by induction of the autophagic 
pathway (Ebrahimi-Fakhari, Wahlster, and McLean 2012). A number of report suggests that 
autophagy itself might be involved in LRRK2 physiological and pathological role, but the 
mechanism underlined is almost unclear [reviewed in (Manzoni 2012)]. The investigation of 
LRRK2-deficient mice displayed a biphasic alteration in autophagy in the kidney (Tong et al. 
2012); however, similar studies in an independent LRRK2-knock out mouse line 
demonstrated an accumulation of secondary lysosomes in the kidney without a major 
involvement of autophagy (Herzig et al. 2011). Even more complex is the state-of-art 
describing autophagy in LRRK2 disease context. In fact a number of authors conclude that 
G2019S mutation increases autophagy in different model, including stable cell line (Gómez-
Suaga et al. 2014; Plowey et al. 2008)8), fibroblast  (Yakhine-Diop et al. 2014), iPS derived 
neurons (Bravo-San Pedro et al. 2013), C.Elegans  (Ferree et al. 2012) and mice  (Ramonet et 
al. 2011). However others studies have reported that the same mutation reduces (Manzoni et 
al. 2013) Oxidative stress including DNA damage, increased lipid and protein oxidation, are 
important features of aging and neurodegeneration suggesting that endogenous antioxidant 
protective pathways are inadequate or overwhelmed. Importantly, oxidative protein damage 
contributes to age-dependent accumulation of dysfunctional mitochondria or protein 
aggregates. In addition, environmental toxins such as rotenone and paraquat, which are risk 
factors for the pathogenesis of neurodegenerative diseases, also promote protein oxidation. 
The obvious approach of supplementing the primary antioxidant systems designed to 
suppress the initiation of oxidative stress has been tested in animal models and positive 
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results were obtained. However, these findings have not been effectively translated to treating 
human patients, and clinical trials for antioxidant therapies using radical scavenging 
molecules such as α-tocopherol, ascorbate and coenzyme Q have met with limited success, 
highlighting several limitations to this approach. These could include: (1) radical scavenging 
antioxidants cannot reverse established damage to proteins and organelles; (2) radical 
scavenging antioxidants are oxidant specific, and can only be effective if the specific 
mechanism for neurodegeneration involves the reactive species to which they are targeted 
and (3) since reactive species play an important role in physiological signaling, suppression 
of endogenous oxidants maybe deleterious. Therefore, alternative approaches that can 
circumvent these limitations are needed. While not previously considered an antioxidant 
system we propose that the autophagy-lysosomal activities, may serve this essential function 
in neurodegenerative diseases by removing damaged or dysfunctional proteins and organelle 
(Giordano, Darley-Usmar, and Zhang 2014)or at least does not affect (Sánchez-Danés et al., 
2012) autophagy. Thus it is still matter of debate if G2019S mutation correlates with an 
increased or a decreased degradative pathway. Even accepting the idea that G2019S 
correlates with an increased autophagic activity, remains open question if G2019S impact on 
autophagy comes as a direct result of kinase hyperactivation or instead is as cellular response 
aiming at rescuing LRRK2 toxicity. In any case, the stimulation of autophagy might 
compensate for low functional UPS and reduce oxidative stress in damaged neurons 
(Giordano, Darley-Usmar, and Zhang 2014). Trehalose is a disaccharide that prevents 
aggregation of denatured proteins inducing their degradation via autophagy. Treatment with 
trehalose demonstrated to be protective in models of Huntington disease, Spinocerebellar 
ataxia and Parkin-PD(Sarkar et al. 2007; Rodríguez-Navarro et al. 2010). Indeed enhancing 
protein degradation via autophagy induction might prove to be a double-edged sword, since 
both reduced and excessive protein degradation can result neurotoxic. Furthermore, the exact 
role and nature of protein aggregates or Lewy bodies in neurodegeneration remains unclear. 
In fact it has been proposed that aggregate form in neurons as a protective mechanism to 
scavenge soluble toxic forms and prolong cellular survival ((Arrasate et al. 2004). Thus, the 
overall consequences of preventing, dissolving or removing mature aggregates are uncertain. 
Notwithstanding all these concerns, we reported here that chronic trehalose treatment reduced 
NSF aggregation and partially ameliorated motor phenotype in aged G2019S mice. The 
pharmacodynamics and the therapeutic profile of trehalose is well established for human 
treatment: thus we deem our results could be translated into the clinical management of PD 
patients. 
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Conclusions  
In this study, we describe how the kinase activating G2019S mutation affects neuronal 
functions and NSF protein accumulation. We depict a scenario where alteration of SV 
dynamics and reduction of the neurite tree accounts for early onset PD symptoms while NSF 
aggregation correlates with late onset defects such as motor deficits. Moreover, we report that 
the chronic treatment with trehalose, an autophagy-inducing molecule, partially recovered the 
motor phenotype and NSF aggregation proposing it as an interesting therapeutic strategy. 
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Abstract 
Background 
Lrrk2, a gene linked to Parkinson’s disease, encodes a large scaffolding protein with 
kinase and GTPase activities implicated in vesicle and cytoskeletal-related processes. At 
the presynaptic site, LRRK2 associates with synaptic vesicles through interaction with a 
panel of presynaptic proteins.  
Results 
Here, we show that LRRK2 kinase activity influences the dynamics of synaptic vesicle 
fusion. We therefore investigated whether LRRK2 phosphorylates component(s) of the 
exo/endocytosis machinery. We have previously observed that LRRK2 interacts with NSF, 
a hexameric AAA+ ATPase that couples ATP hydrolysis to the disassembling of SNARE 
proteins allowing them to enter another fusion cycle during synaptic exocytosis. Here, we 
demonstrate that NSF is a substrate of LRRK2 kinase activity. LRRK2 phosphorylates full-
length NSF at threonine 645 in the ATP binding pocket of D2 domain. Functionally, NSF 
phosphorylated by LRRK2 displays enhanced ATPase activity and increased rate of 
SNARE complex disassembling. Substitution of threonine 645 with alanine abrogates 
LRRK2-mediated increased ATPase activity.  
Conclusions 
Given that the most common Parkinson’s disease LRRK2 G2019S mutation displays 
increased kinase activity, our results suggest that mutant LRRK2 may impair synaptic 
vesicle dynamics via aberrant phosphorylation of NSF. 
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Parkinson’s disease, Leucine-rich repeat kinase 2, N-ethylmaleimide sensitive fusion, 
presynapse, phosphorylation 
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Background 
Leucine-rich repeat kinase 2 (LRRK2) is a large kinase with protein-to-protein interaction 
domains and dual enzymatic activities. The catalytic core includes a ROC (Ras Of 
Complex) domain with GTPase activity, followed by a COR (C-terminus Of ROC) domain 
likely involved in protein dimerization, and a serine-threonine kinase domain [1-3]. 
Mutations in Lrrk2 cause late-onset autosomal dominant Parkinson’s disease (PD) [4,5], 
whereas more common variants around the Lrrk2 locus act as risk factors for disease 
[6,7]. As the most common G2019S mutation increases kinase activity in vitro and in vivo 
by ~3 fold, LRRK2 is being intensively explored as a pharmacological target for the 
treatment of PD [8]. Several substrates of LRRK2’s kinase activity have been reported, 
however few of these have been extensively validated at a physiological level [9]. There is, 
therefore, an increasing interest in identifying LRRK2 substrates and cellular pathways 
compromised during pathological conditions that could serve as therapeutic alternatives to 
directly targeting LRRK2 kinase activity. LRRK2 has been found associated with various 
membrane structures, including synaptic vesicles (SV) [10-15]. Multiple studies on different 
experimental models support a role for LRRK2 at the synapse. Mutant LRRK2 rodent 
models display defects in neurotransmission [16-19], and LRRK2 overexpression or 
knockdown results in impaired SV endocytosis/exocytosis [15,20]. We recently showed 
that LRRK2 binds SV via interaction with a number of presynaptic proteins [21] and that its 
kinase activity modulates these interactions and impacts on SV dynamics [22]. Among the 
LRRK2 interactors identified, we found N-ethylmaleimide sensitive factor (NSF), which is 
involved in the fusion of SV orchestrated by SNARE (Soluble NSF-Attachment protein 
REceptor) proteins. During membrane fusion, vesicular and target SNAREs assemble into 
an alpha-helical trans-SNARE complex that juxtaposes the two membranes together to 
catalyze membrane fusion. NSF is the ATPase that catalyzes the release of SNARE 
complexes, thus allowing SV endocytosis and the next cycle of fusion [23]. Notably, NSF 
activity is tightly controlled by phosphorylation/dephosphorylation [24-26]. In the present 
study, using dynamic assays of SV cycling, we found that SV fusion is altered by LRRK2 
kinase function, suggesting components of the exo/endocytic machinery may be a target 
of LRRK2 kinase activity. Given that LRRK2 interacts with NSF, we assessed whether 
NSF is a substrate for LRRK2 kinase activity. We found that LRRK2 can efficiently 
phosphorylate NSF in vitro, with phosphorylation primarily occurring at T645. Importantly, 
phosphorylated NSF displays enhanced ATPase activity and increased rate of SNARE 
complex disassembling in vitro. Our data implicate LRRK2 kinase activity in the regulation 
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of SV exo/endocytosis by phospho-modulation of NSF activity and suggest that 
pathological LRRK2 may disturb SV dynamics via aberrant phosphorylation of NSF.  
 
Results 
LRRK2 kinase activity influences synaptic vesicle dynamics 
We recently reported that inhibition of LRRK2 kinase activity causes impairment in 
synaptic vesicles (SV) dynamics, indicating a role for LRRK2 catalytic activity in SV fusion 
cycle [22].  To further determine the role of LRRK2 kinase activity at the presynapse, we 
performed dynamic assays of SV taking advantage of the sypHy assay in two 
complementary models: a) primary cortical cultures in the presence or absence of the 
LRRK2 inhibitor GSK2578215A (GSK in, 0.2 PM, 2h), a brain penetrant, selective LRRK2 
inhibitor (IC50 10 nM) [27]; b) primary cortical neurons obtained from BAC hG2019S mice 
characterized by higher LRRK2 kinase activity [28]. GSK treatment induced LRRK2 
dephosphorylation at Ser935, as predicted (Fig. S1-b), but did not cause protein 
destabilization (Fig. S1a-c), whereas BAC hG2019S neurons displayed increased LRRK2 
expression due to the presence of the transgene (Fig. S1a-b-c). Synaptophysin-pHluorin 
(sypHy) is a pH-sensitive fluorescent reporter that, by analogy with the original 
synaptopHluorin (synaptobrevin-pHluorin), is quenched in the acidic intracellular space of 
the SV and will only become fluorescent upon SV fusion, when the contents of the SV is 
exposed to the more basic pH of the extracellular space [29]. As shown in figure 1, at the 
onset of the stimulus, exocytosis caused a rapid increase in sypHy fluorescence, which 
after cessation of the stimulus, slowly returned to baseline (Fig. 1a-b). The first stimulus, 
40 AP, is predicted to mobilize SV belonging to the ready releasable pool, while 300 AP is 
sufficient to trigger the fusion of SV belonging to the total recycling pool [29]. Furthermore, 
the kinetics describing the on-set and the decay of the fluorescence are correlated to the 
efficiency of the exocytotic and endocytotic mechanism, respectively [29]. Interestingly, 
while we measured a significant impairment of SV fusion (decreased fluorescence) in the 
presence of GSK upon either 40 or 300 AP stimuli, BAC hG2019S neurons were 
characterized by a higher answer following the two stimulations ('F40/F0 and 'F300/F0 
respectively, fig. 1c). Furthermore, while upon acute pharmacological inhibition the time 
taken for fluorescence decay was extended, W decay was decreased in hG2019S cells 
(Tau decay, fig. 1c). To further assess a role for LRRK2 in the SV cycle, we took 
advantage of the exo/endocytic assay previously reported [20,21]. Using this approach, we 
previously demonstrated that acute pharmacological blockade of LRRK2 kinase activity 
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impairs SV recycling [22]. Building upon these data, BAC hG2019S cortical cultures were 
transduced at DIV4 with control viruses co-expressing GFP to track neuronal processes 
and assayed at DIV14. Briefly, we exposed living cultures to rabbit polyclonal antibodies 
directed against the intravesicular domain of synaptotagmin1, which are internalized inside 
the vesicle lumen upon SV recycling [30]. Vesicles within GFP positive processes were 
then monitored via laser confocal microscopy. The vesicles appeared as clusters either 
synaptotagmin and synaptophysin positive (i.e. cycling vesicles) or only synaptophysin 
positive (Fig. 1d). The analysis showed that BAC hG2019S cultures are characterized by a 
significant increase in the number of synaptotagmin and synaptophysin positive clusters 
(Fig. 1e). The total number of synaptic contacts, however, remained unaltered despite any 
pharmacological treatments (Fig. S1d). Taken together, these results indicate that LRRK2 
kinase activity is involved in the regulation of SV fusion. 
 
LRRK2 interacts with NSF 
Having found that LRRK2 kinase activity influences SV fusion, we next asked what the 
molecular mechanisms behind this phenotype might be. We had previously demonstrated 
that LRRK2 interacts with the vesicle fusing ATPase NSF through its WD40 domain [21].  
We first confirmed LRRK2 and NSF interaction at the endogenous level in synaptosomal 
preparations. Using co-immunoprecipitation with endogenous proteins from rat 
synaptosomes, we observed that LRRK2 efficiently co-precipitates NSF (Fig. 2a). Next, we 
dissected the domain(s) of NSF involved in binding LRRK2. To this aim, we cloned human 
full-length NSF (aa 1-744) and its different domains, namely N domain (aa 1-205), D1 
domain (aa 206-487) and D2 domain (aa 488-744) in fusion with a N-terminal Flag-tag and 
purified the proteins from HEK293T cells. Proteins bounds to Flag-conjugated beads were 
adjusted to equal molar concentrations and subsequently incubated with a mouse brain 
lysate. As shown in figure 2b, full-length NSF pulls-down endogenous LRRK2. 
Interestingly, N and D2 domains, but not D1, also pull-down endogenous LRRK2 (Fig. 2b). 
To further confirm the interaction between LRRK2 and NSF, we used size exclusion 
chromatography (SEC) to fractionate HEK293T lysates expressing Flag-NSF or co-
expressing Flag-NSF and 2xMyc-LRRK2, followed by dot blot analysis. As shown in figure 
2c, NSF elutes between 11 mL and 17.5 mL. Interestingly, in the presence of LRRK2, NSF 
elution profile shifts toward shorter retention times (elution peak between 10 mL and 16.5 
mL) suggesting the formation of a complex with higher molecular weight than NSF alone 
(Fig. 2c). We also evaluated the cellular localization of endogenous NSF and LRRK2 in 
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primary neuronal cultures and found that the two proteins largely co-localize, and co-
localization is enriched within clusters along the neurites (Fig. 2d). Collectively these data 
indicate that LRRK2 and NSF form a complex in the cell.  
 
LRRK2 phosphorylates NSF in D2 domain  
LRRK2 affects SV dynamics via its kinase activity (Fig. 1a-c) [22]. Therefore, we 
hypothesized that NSF could be a substrate of LRRK2 and, as such, be involved in the 
LRRK2 kinase dependent regulation of SV. To test this hypothesis, we performed in vitro 
kinase assays using recombinant LRRK2 and NSF purified from mammalian cells. We first 
validated recombinant human NSF biochemically. NSF purified as described in the 
methods section folds into hexamers when loaded with 1 mM ATP as evidenced by 
negative-stain transmission electron microscopy (TEM) (Fig. S2a). Of interest, Flag-tagged 
NSF purified with Flag affinity resin co-precipitates endogenous NSF as indicated by the 
presence of a band corresponding to endogenous NSF (Fig. S2b), further supporting the 
notion that Flag-NSF forms oligomers. To verify that purified NSF is functional, we 
measured ATP to ADP hydrolysis rate by isocratic reverse-phase HPLC (Fig. S2c-d) and 
malachite green colorimetric assay (Fig. S2e). NSF efficiently hydrolyzes ATP to ADP over 
time under these purification and assay conditions. 
Having validated recombinant human full-length NSF, we next purified soluble 3xFlag-
LRRK2 wild-type, the hyperactive clinical mutant G2019S and the kinase dead K1906M 
from HEK293T cells and subsequently incubated these purified proteins with full-length 
NSF in kinase assay conditions [31]. As shown in figure 3a, at a 1:10 ratio of LRRK2:NSF, 
we observe robust phosphorylation of NSF by LRRK2. Importantly, in the presence of 
LRRK2 K1906M or upon addition of 1 µM LRRK2 IN-1 inhibitor, NSF phosphorylation 
corresponds to the background levels observed for NSF alone, confirming that the 
incorporation of radioactive phosphate is genuinely due to LRRK2 kinase activity  (Fig. 3a). 
We confirmed LRRK2-mediated phosphorylation of NSF using the hyperactive G2019S-
LRRK2970-2527 fragment (Fig. 3b). The stoichiometry of phosphate incorporation, measured 
using a calibration curve with different concentrations of 33P-ATP, is approximately 0.04 
moles of phosphate per mole of monomeric NSF in the presence of LRRK2 wild-type, 0.1 
in the presence of G2019S and 0.4 with an artificial truncated variant characterized by 
higher activity, G2019S-LRRK2970-2527 (Fig. 3c). The low value for this stoichiometry, when 
taken in the context of a hexameric NSF complex, is sufficient to imply the presence of at 
least one phosphorylated monomer per hexamer. The reaction reached a plateau after 1-
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hour incubation (Fig. S3a-b), likely due to inactivation of LRRK2 under assay conditions as 
previously reported [32].  
To define the region(s) of NSF phosphorylated by LRRK2, we performed kinase assays in 
the presence of NSF full-length or isolated domains. While we failed to detect any 
phosphorylation when N and D1 domains were incubated with G2019S-LRRK2970-2527, we 
were able to measure phosphate incorporation in the D2 domain (Fig. 3d). Importantly, 
NSF is not a substrate of the cognate protein LRRK1 under these assay conditions (Fig.  
3e), suggesting that this phosphorylation event is specific to LRRK2. In toto, these results 
indicate that LRRK2 likely phosphorylates the D2 domain of NSF. 
 
LRRK2 phosphorylates NSF at threonine 645. 
We next set out to identify NSF phosphorylation site(s) targeted by LRRK2. To achieve 
this, we used phospho-peptide enrichment coupled with liquid chromatography/tandem 
mass spectrometry (LC-MS/MS) analysis on purified NSF pretreated with alkaline 
phosphatase to eliminate possible cellular phosphorylation sites, and subsequently 
phosphorylated by LRRK2 in vitro. Under the experimental conditions used, we were able 
to achieve ≈80% NSF sequence coverage (Fig. S4a) and identified the peptide 
639KLLIIGTTSR648 as a bona fide phospho substrate. The MS analysis could not 
discriminate whether single/multiple phosphorylation occurred at T645, T646 or S647 or 
whether these sites may be multi-phosphorylated (Fig. S4b). This phosphopeptide was 
enriched following incubation with wild-type and G2019S LRRK2, but not in control 
samples (LRRK2 kinase dead or in the presence of 1 µM IN-1) indicating it contains 
specific LRRK2 phosphorylation site(s). We next validated the MS data by site-direct 
mutagenesis and in vitro kinase assays. Wild-type and phospho-deficient NSF mutants 
T645A, T646A and S647A were expressed and purified in HEK293T cells and 
subsequently incubated in vitro with catalytically active LRRK2 under phosphorylation 
permissive conditions. T645A displayed ~50% reduction of 33P incorporation compared to 
NSF wild-type, T646A and S647A (**p<0.01, One-Way ANOVA with Bonferroni’s post-
test). Since NSF is also phosphorylated by PKC but within a different residue (S237) [26], 
we next assessed whether PKC is able to phosphorylate NSF at T645 to rule out any 
promiscuous effect. As shown in figure S5, we confirm that PKC efficiently phosphorylates 
NSF in vitro, but NSFT645A exhibits similar 33P incorporation as NSF wild-type, suggesting 
that T645 is a LRRK2 specific phospho-site. Overall, our data indicate that T645 is a 
LRRK2 phosphorylation site within NSF. 
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LRRK2-mediated phosphorylation increases NSF ATPase activity  
We next investigated whether LRRK2 mediated phosphorylation of NSF has a functional 
consequence on its ATPase activity. We first identified the optimal detergent 
concentrations at which both LRRK2 and NSF display maximal catalytic activity (0.007% of 
polysorbate 20, the critical micelle concentration of the detergent; Fig. S6). Subsequently, 
full-length NSF was exposed to LRRK2-G2019S970-2527 or buffer in kinase assays 
conditions (with 50 µM ATP to minimize interference with the subsequent ATPase assay) 
for 30 min. As shown in figure 5a, NSF phosphorylated by LRRK2 exhibits increased 
ATPase activity (Km=355±50 µM; kcat=40±11 min-1; Vmax=0.95±0.22 µmol/min, from n=4 
independent purifications) compared to unphosphorylated NSF (Km=178±12 µM; kcat=19±4 
min-1; Vmax=0.37±0.07 µmol/min, from n=4 independent purifications). Given that we 
identified threonine 645 as a bona fide LRRK2 target, we next assessed the ATPase 
activity of NSFT645A, along with NSF wild-type, NSFT646A and NSFS647A, pre-treated with 
LRRK2-G2019S970-2527 or buffer control in kinase assay conditions. As shown in figure 5b, 
NSFT645A displays impaired ability to hydrolyze ATP and, importantly, activity could not be 
restored when NSFT645A is pre-phosphorylated by LRRK2. Interestingly, the neighboring 
T646 mutated to alanine also exhibits impaired ATPase activity that cannot be recovered 
by LRRK2 phosphorylation, whereas NSFS647A, two residues apart from T645, displays 
ATPase activity similar to wild-type, and this activity is enhanced by LRRK2 
phosphorylation. These results strongly indicate that T645 and T646 are critical for NSF 
catalytic activity. To rule out that NSFT645A impaired activity was due to partial unfolding, 
we used circular dichroism (CD) and fluorescence spectroscopy to compare the secondary 
structures of NSF wild-type and NSFT645A.  Tryptophan fluorescence is similar among wild-
type and NSFT645A (Fig. S7a). CD spectra also confirm that the overall folding is 
maintained (Fig. S7b). In addition, TEM imaging confirms that NSFT645A retains the ability 
to form hexamers (Fig. S7c). Taken together, these data indicate that NSF phosphorylated 
by LRRK2 possesses enhanced ATPase activity and T645 is a crucial site for enzymatic 
catalysis. 
 
LRRK2-mediated phosphorylation of NSF increases the rate of SNARE complex 
disassembling  
NSF-mediated ATP hydrolysis promotes disassembly of the SNARE complex [33]. Given 
that NSF phosphorylation by LRRK2 increases its ATPase activity (Fig. 5), we next 
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postulated that this also impacts upon the rate of SNARE complex dissociation. To test 
this, we monitored the kinetic of SNARE complex disassembling in vitro as previously 
described [34,35]. We co-expressed in E. coli recombinant soluble syntaxin, SNAP-25 and 
6xHis-VAMP and purified the assembled complex by IMAC affinity purification followed by 
size exclusion chromatography [35]. As shown in figure S8, the complex elutes as single 
band corresponding to the expected molecular weight for the soluble SNARE complex (68 
kDa), which is dissociated into the three SNARE components upon heating. To assess 
whether LRRK2 phosphorylation on NSF impacts the rate of SNARE complex 
disassembling in vitro, we incubated SNARE complex (480 nM) with 1.5 µM of alpha-
SNAP, an essential co-factor, and 24 nM of NSF (phosphorylated or not by LRRK2) in the 
presence of 2 mM of ATP, and subsequently analyzed the kinetic of SNARE complex 
disappearance over 150 minutes. Under these assay conditions, NSF phosphorylated by 
LRRK2 displayed a markedly increased efficiency in disassembling SNARE complex 
compared to non-phosphorylated NSF (Fig. 6a-b). These data further support the notion 
that LRRK2-mediated phosphorylation increases NSF catalytic activity with consequent 
acceleration of the disassembly of SNARE complexes in vitro.  
 
Discussion 
Identification of heterologous substrates of LRRK2 kinase activity is essential for 
understanding the cellular pathways deregulated in PD caused by mutations in this gene 
[3]. Here we provided evidence that the presynaptic ATPase NSF is a substrate of LRRK2 
kinase activity, and that phosphorylated NSF displays enhanced ATP hydrolysis and 
SNARE complex dissociation activity in vitro.  
Multiple lines of evidence support a role of LRRK2 at the presynaptic compartment. We 
previously found that LRRK2 controls SV storage and mobilization within the recycling pool 
[20] and that this process is dependent on LRRK2 kinase activity [22]. Synaptosomes 
treated with LRRK2 inhibitors exhibit decreased evoked glutamate release [22] whereas 
elevated glutamate release and synaptic transmission were observed in LRRK2 G2019S 
knock-in mice [16]. Altogether, these data indicate that LRRK2 kinase may play an 
important role in modulating a step of the exo-endocytic pathway. LRRK2 is a complex 
kinase with several protein interaction domains, which was shown to assemble 
multiprotein complexes during signal transduction [11]. At the presynapse, LRRK2 
interacts with several proteins [21]. Moreover, accumulating literature suggests that 
LRRK2 regulates SV dynamics via phosphorylation of presynaptic proteins, such as 
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Snapin, and EndophilinA [36-38]. The present work provides evidence that NSF is not only 
an interactor but also a substrate of LRRK2 in vitro.  Recently, another LRRK2 interactor, 
the ribosomal protein s15, has been shown to serve as LRRK2 substrate [39], further 
emphasizing the value of examining LRRK2 interacting proteins as potential kinase 
substrates.  
Here, we demonstrated that LRRK2 phosphorylates NSF at T645. The functional 
consequence of this is that NSF hydrolyses ATP faster when phosphorylated by LRRK2 at 
this residue. The physiological relevance of this finding is further supported by the 
observed increased rate of SNARE complex disassembling in the presence of 
phosphorylated NSF. Indeed, we found T645A is characterized by a reduced endogenous 
ATPase activity. Given that T645 is located within the D2 domain of NSF, which is thought 
to be important for NSF oligomerization via ATP binding [40], these results are consistent 
with our current understanding of NSF function. Specifically, T645 is part of the beta strand 
S4 (aa 639-646), which stabilizes the hexamer through interaction with the neighboring 
alpha-helix H5 [41]. Therefore, T645 is predicted to be a key residue for protein 
oligomerization, which impacts the ability of the D1 domain to hydrolyze ATP. Clearly, 
further investigation is merited to determine whether LRRK2 phosphorylation at T645 
directly alters NSF oligomerization.  
Translating these findings into the neuronal context, these data imply that LRRK2 may 
play a role in tuning the kinetics of SV fusion by accelerating SNARE complex dissociation 
via NSF phosphorylation. Previous studies reported NSF as substrate of other serine-
threonine kinases: NSF is phosphorylated by Pctaire1 at S569 in the D2 domain, and this 
phosphorylation reduces NSF oligomerization [25]; NSF is also phosphorylated by PKC in 
vitro at Ser-237 of the catalytic D1 domain which negatively regulate NSF binding to alpha-
SNAP-SNARE complexes (Fig. S5) [26]. Therefore, both Pctaire1 and PKC appear to 
switch off NSF activity. In our current study, we report multiple strands of evidence that 
suggest that NSF phosphorylated by LRRK2 is more active in vitro, however it is still 
unknown whether this is replicated in vivo. Wild-type LRRK2 is characterized by a low 
basal activity that may become pathologically relevant in the presence of gain of function 
mutations. We predict that in the presence of pathological hyperactive LRRK2 variant, SV 
endocytosis may be abnormally fast. Such alteration could result in 1) increased 
neurotransmitter release or 2) impaired neurotransmitter release by accelerating SV 
endocytosis. While the second hypothesis would fit with the reduced dopamine release 
observed in mice expressing LRRK2 G2019S selectively in midbrain dopaminergic 
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neurons [42], increased glutamate release has been reported in G2019S knock-in neurons 
[16] – consistent with the first hypothesis. Thus, additional research is needed to clearly 
identify the best representative model of LRRK2 function and dysfunction in the neuron.  
We also provide robust evidence that the kinase activity of LRRK2 affects SV dynamics 
using two complementary models: LRRK2 inhibition and hyperactive LRRK2 (BAC 
hG2019S) in primary cortical neurons. The strong impairment of SV exo-endocytosis 
observed in the presence of pharmacological inhibition (Fig. 1, [22]) suggests that a 
consequence of therapeutic LRRK2 kinase inhibition might be alterations in the biology of 
the presynaptic compartment, likely impairing neurotransmitter release and synaptic 
function. These observations, together with the reported side effects in peripheral organs 
[43] suggest that additional strategies should be considered to target pathological LRRK2 
function. 
 
Conclusions 
In the present study, we report LRRK2 kinase as a positive regulator of NSF activity and 
SNARE complex disassembling in vitro. Future studies should also be directed at 
understanding whether this phosphorylation is relevant in the pathogenesis of PD.  
 
Methods 
Animals, neuron cultures and drugs. 
Housing and handling of mice were carried out in compliance with the guidelines 
established by the European Community Council (Directive 2010/63/EU of March 4th, 
2014) and approved by the Italian Ministry of Health (IACUC 625). Non-transgenic wild-
type and LRRK2 BAC hG2019S mice, back-crossed on a C57BL/6J strain, were obtained 
from Mayo Clinic (Jacksonville, FL, USA) through a collaboration with Dr. Heather Melrose 
[28]. Animals were kept following guidelines of Ministry of Education, Universities and 
Research (MIUR). Neuron cultures were prepared from either mouse cortexes or 
hippocampi obtained from embryonic day 15.5-16.5 mice (C57BL/6J). High-density (750-
1000 cells/mm2) and medium-density (150–200 cells/mm2) neuron cultures were plated 
and grown as described on 12-well plastic tissue culture plates (Iwaki; Bibby Sterilin 
Staffordshire, UK) or on 12 mm diameter coverslips put into 24-well plastic tissue culture 
plates (Iwaki) [44]. GSK-2578215A compound (Tocris Bioscience, Bristol, UK) or DMSO 
were added to culture media at the concentrations indicated through the text. For 
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immunocytochemistry, primary cultured neurons were fixed with 4% paraformaldehyde 
and probed with primary rabbit anti-NSF (1:200, D31C7, Cell Signaling, Danvers, MA, 
USA) and mouse anti-LRRK2 (1:200 N231B/34, NeuroMab, Davis, CA, USA) and 
secondary anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 (Thermo Fisher, 
Waltham, MA USA). 
 
Plasmids and constructs  
pCHMWS 3xFlag-tagged LRRK2 wild-type, K1906M and G2019S, 2x-Myc LRRK2 
constructs have been previously described [31]. NSF constructs (full-length and domains) 
were cloned into p3XFLAG-CMV-7.1 vector (Sigma-Aldrich, St. Louis, MO, USA). NSF 
domains were amplified using forward primers with NotI overhang and reverse primers 
with KpnI overhang as following: 
N-Domain (1-205): forward 5’-AAGCTTGCGGCCGCCTTCGCGGGCCGGAGC-3’ and 
reverse 5’-TCGACTGGTACCTTAGCGATTTTCCTTGGTTTT-3’ 
D1 domain (206-477aa): forward 5’-AAGCTTGCGGCCGCCCAATCAATTATCAATC-3’ 
and reverse 5’-TCGACTGGTACCTTATCTCGTCACTTGCAGGC-3’ 
D2 domain (478-744aa): forward 5’-AAGCTTGCGGCCGCCGGAGACTTCCTTGCTTC-3’ 
and reverse 5’-TCGACTGGTACCTCAATCAAAATCAAGGGG-3’. 
NSF mutants were generated using the QuickChange mutagenesis kit (Agilent 
Technologies, CA, USA) according to the manufacturer's instructions. All plasmids were 
validated by restriction analysis and DNA sequencing. 
 
Cell culture and transfection  
Human embryonic kidney cells (HEK293T) were cultured in Dulbecco's modified Eagle's 
medium (DMEM, Thermo Fisher, Waltham, MA USA) supplemented with 10% fetal bovine 
serum (FBS, Thermo Fisher, Waltham, MA USA) at 37°C and 5% CO2. HEK293T were 
transiently transfected using linear polyethylenimine (PEI, Polysciences) with ratio 
DNA:PEI 1:2. 40 μ g of DNA were dissolved in 1ml of OPTI-MEM (Thermo Fisher, 
Waltham, MA USA) and 80 µl of PEI (40 µM) were added to 1ml of OPTI-MEM. After 5 
minutes of incubation the two solutions were mixed together and incubated for 20 minutes 
to allow the formation of DNA/PEI complexes. Then, the mix was added directly to the 
cells in Petri dishes of 15 cm2 and used after 48-72 hours.  
 
Antibodies, SDS-PAGE and western blot analysis 
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Antibodies used for western blotting were as follows: anti-Flag M2 (1:10000, Sigma-
Aldrich, St. Louis, MO, USA); anti-NSF (1:500, Cell Signaling, Danvers, MA, USA); anti-
LRRK2 (1:1000, C41-2, Abcam, Cambridge, UK); anti-Synaptobrevin, anti-synaptophysin 
and anti-Synaptotagmin 1 (1:1000, Synaptic System, Göttingen, Germany). 
Between 10 and 20 µg of protein samples were dissolved in 4-20% Tris-glycine 
polyacrylamide gels (Biorad) in SDS/Tris-glycine running buffer. Precision Plus molecular 
weight markers (Biorad) were used for size estimation. Solubilized proteins were then 
transferred to polyvinylidenedifluoride (PVDF) membranes in transfer buffer containing 
10% methanol. The PVDF sheets were blocked in Tris-buffered saline plus 0.1% Triton 
(TBS-T) plus 5% nonfat dry milk for 1 hour at 4°C and then incubated overnight at 4°C with 
primary antibody in TBS-T plus 5% non-fat dry milk. The PVDF membranes were washed 
in TBS-T (3x10 min) at room temperature (RT) followed by incubation for 1 h at RT with 
horseradish peroxidase-conjugated anti-mouse IgG. Blots were then washed in TBS-T 
(4x10 min) at RT and rinsed in TBS, and immunoreactive proteins were visualized using 
enhanced chemiluminescence plus (ECL+, GE Healthcare, Waukesha, WI, USA). 
Densitometric analysis was carried out using Image J software. 
 
Protein purification  
Human NSF with a N-terminal Flag tag or NSF domains were purified from HEK293T cells 
after transient transfection as described above. Cells were resuspended in 1 ml of a lysis 
buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM Na4P2O7, 1 mM beta-
glycerophosphate, 1mM Na3VO4, Protease Inhibitor Mixture (Sigma-Aldrich, St. Louis, MO, 
USA)) and then lysed with 5 cycles of freezing and thawing in liquid nitrogen. The cell 
lysate was collected after centrifugation at 18000xg for 40 minutes at 4°C. The 
supernatant was incubate overnight with 40 µl of Anti-Flag M2 Affinity gel (Sigma-Aldrich, 
St. Louis, MO, USA) at 4°C. After centrifugation, the supernatant was discarded and the 
beads with human NSF were washed with 1 ml of different buffers: WB1 (20 mM Tris-HCl 
pH 7.5, 500 mM NaCl) twice, WB2 (20 mM Tris-HCl pH 7.5, 350 mM NaCl) twice, WB3 (20 
mM Tris-HCl pH 7.5, 150 mM NaCl) six times. The protein was then eluted by incubating 
the beads with 200 µl of 20 mM Tris-HCl pH 7.5, 150 mM NaCl or directly in the kinase 
assay buffer (25 mM Tris-HCl pH 7.5, 5 mM beta-glycerophosphate, 2 mM DTT, 0,1 mM 
Na3VO4, 10 mM MgCl2) with 150 ng/µl 3xFlag peptide and mixing the sample for about 2 
hours. The sample was centrifuged to pellet the resin and the supernatant was collected. 
Note that all the purification steps were carried out in the absence of detergent, a condition 
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that resulted essential to maintain NSF folding and to detect specific phosphorylation by 
LRRK2. Purified human NSF was separated on SDS-PAGE and quantified by comparison 
with different concentrations of BSA (Bovine Serum Albumin). Proteins were 
electrophoretically resolved on 4–20% Tris-glycine polyacrylamide gels (Biorad) using 
SDS/Tris-glycine running buffer. To estimate the molecular weight of proteins Precision 
Plus molecular weight marker (Biorad) was used. After the run, proteins were stained with 
Coomassie Brillant blue to enable the quantification with ImageJ software.  
 
Synaptosomes preparation and immunoprecipitation 
Brains from adult rats were quickly removed and the cerebral cortex dissected out at 4°C. 
Purified synaptosomes were prepared on Percoll gradients (Sigma-Aldrich, St Louis, MO, 
USA) essentially according to Nakamura et al. with minor modifications [45]. Briefly, the 
tissue was homogenized in 14 volumes of 0.32 M sucrose, Tris–HCl pH 7.4, using a glass-
teflon tissue grinder (clearance 0.25 mm, 12 up–down strokes in about 1 min). The 
homogenate was centrifuged (5 min, 1000g at 4°C) to remove nuclei and debris and the 
supernatant was gently stratified on a discontinuous Percoll gradient (2%, 6%, 10%, and 
20% v/v in Tris-buffered sucrose) and centrifuged at 33500g for 5 min at 4°C. 
The layer between 10% and 20% Percoll (synaptosomal fraction) was collected, washed 
by centrifugation and resuspended in RIPA buffer (NaCl 150mM, Tris 50mM (pH 7.4), 
NP40 (1%v/v), SDS (0.1%v/v) and protease inhibitors). To precipitate the 
immunocomplexes the extract was incubated for 2h at RT with anti-LRRK2 antibodies 
(10µg/sample; MJFF C41-2, Abcam, Cambridge, UK) or a control rabbit IgG 
(10µg/sample; Sigma-Aldrich, St. Louis, MO, USA) conjugated with 25μl of settled 
prewashed protein G-Sepharose beads (GE-Healthcare, Waukesha, WI, USA). The eluted 
proteins were separated by SDS-PAGE, transferred onto nitrocellulose membrane (GE-
Healthcare, Waukesha, WI, USA) and analyzed by western-blotting with anti-LRRK2 and 
anti-NSF (Cell Signaling, Danvers, MA, USA) antibodies. Western-blotting with anti-
synaptotagmin 1, anti-synaptophysin and anti-synaptobrevin were performed to confirm 
purity of synaptosomal preparation. 
 
Pull-down assays 
NSF domains and full length NSF were purified after transient transfection from HEK293T 
cells. Cells were harvested in 500 µl of Lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 
2.5 mM Na4P2O7, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 0.27 M Sucrose, 1% Triton 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  15 
X-100, Protease Inhibitor Mixture (Sigma-Aldrich, St. Louis, MO, USA)). The cell lysate 
was then centrifuged at 18000xg for 30 minutes at 4°C. Subsequently, the lysate was 
incubated overnight with 20 µl of Anti-Flag M2 Affinity gel (Sigma-Aldrich, St. Louis, MO, 
USA) at 4°C. After centrifugation, the supernatant was discarded and the beads with NSF 
proteins were washed 3 times with 1 ml of a Washing buffer (50 mM Tris-HCl pH 7.5, 1 
mM EDTA, 0.27 M Sucrose, 250 mM NaCl, 0.02% Triton X-100) and resuspended in 100 
µl of the same buffer. Proteins were loaded on an SDS-PAGE gel and their concentration 
was quantified measuring the intensity of the band against known BSA standards with 
ImageJ software.  
Proteins were subsequently adjusted to the same concentration (2 µM) and incubated with 
600 µl mouse brain lysate (2.5 mg/ml concentrated) overnight at 4°C. The day after, resins 
were boiled with sample buffer, loaded into a SDS-PAGE gel and transferred onto PVDF 
membranes. 
 
Size Exclusion Chromatography (SEC) and dot blot analysis 
Flag-NSF alone or Flag-NSF and 2xmyc-LRRK2 transfected HEK293T cells were lysed in 
500 µl of lysis buffer containing 0.06 % (v/v) Triton X-100 and centrifuged. Cell lysates 
clarified were separated on a Superose 6 10/300 column (Ge Healthcare, Waukesha, WI, 
USA) pre-equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.06% (v/v) Triton 
X-100. The flow rate used was 0.5 ml/min. A calibration curve was produced using the 
following proteins and relative elution volumes: 7.5 ml for Blue Dextran (void volume), 11.5 
ml for hemocyanin from Carcinus aestuarii (900 kDa), 12 ml for thyroglobulin (669 kDa), 14 
ml for ferritin (440 kDa) and 12.5 ml for catalase (232 kDa). Fractions of 0.25 ml were 
collected and spotted onto a nitrocellulose membrane and analyzed by dot blot. The 
membrane was blocked with 10% milk in TTBS and incubated with mouse monoclonal 
anti-Flag M2-peroxidase (Sigma-Aldrich, St. Louis, MO, USA) or anti-myc (Roche) in TTBS 
with 10% milk. A secondary rabbit antibody (Sigma-Aldrich, St. Louis, MO, USA) was used 
to stain the anti-myc. Immunoproteins were visualized using ECL (GE, Healthcare, 
Waukesha, WI, USA). 
 
Electron microscopy  
Purified NSF proteins were incubated with 1mM ATP and 2 mM MgCl2.  A total of 15 ng of 
protein was adsorbed few minutes to a glow-discharged carbon-coated copper grid, 
washed with deionized water, and stained with 1% uranyl acetate. Images were collected 
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using a Fei Tecnai T12 electron microscope equipped with a LaB6 filament and operated 
at an acceleration voltage of 100 kV. 
 
In vitro Kinase Assay 
Purified NSFs eluted in kinase assay buffer were incubated with LRRK2 proteins dissolved 
in kinase buffer for 1 hour at 30 °C in the presence of 33P-ATP (1 µCi) and 10 µM cold ATP 
as previously described [31]. 
Incorporated 33P-ATP was detected by autoradiography or by Phospho-Imager system 
(Cyclone, Perkin-Elmer). The same membranes were probed with anti-Flag antibody for 
total protein loading and analyzed using ImageJ software.  
 
SypHy assay 
We infected DIV4 primary neurons with viruses expressing sypHy, a fusion construct of 
synaptophysin and super ecliptic pHluorin [29]. At DIV14 neurons were treated with DMSO 
(control) or GSK2578215A (0.2 PM, 2 hours). Syphy positive boutons were assayed in a 
stimulation chamber on the stage of a Zeiss Axiovert 200M equipped with a mono-
chromator (Poly V) and a cooled CCD camera (PCO, Imago QE), both from TILL photonics 
(Gräfelfing, Germany). The assay was carried out as described previously [46]. Briefly, 
cells were submerged in 500 μl of KRH buffer (125 mM NaCl, 5 mM KCl, 1.8 mM CaCl2 
2.6 mM MgSO4 5 mM Hepes, pH 7.2) in presence of APV (2PM, Sigma-Aldrich, St. Louis, 
MO, USA) and CNQX (2PM, Sigma-Aldrich, St. Louis, MO, USA). SypHy was excited at 
475 nm and its fluorescence emission collected at 525 nm using a 60X, 1.1 NA water 
immersion objective. Images were acquired every second for 200 seconds using TillVision 
software (TILL Photonics). At frame 30, cells were stimulated with 40 action potential (AP, 
20Hz) then at frame 70 with 300 AP (20 Hz). Total fluorescence was measured upon 
incubation with 50 mM NH4Cl. Quantitative measurements of the fluorescence intensity at 
individual boutons were obtained by averaging a selected area of pixel intensities using 
ImageJ. Net fluorescence changes (ΔF) were obtained by subtracting the average 
intensity of the first 15 frames (F0) from the intensity of each frame (Ft) for individual 
boutons and normalized F0 (ΔF/F0). The fluorescence increase and decay, reflect exo- 
and endocytosis, respectively [29]. Both the fluorescence upstroke and decay were fitted 
with a single exponential τ (τupstroke and τdecay respectively). Data are expressed as mean ± 
SEM and statistical significance was assessed by unpaired two-tailed Student’s t test 
(GraphPad Prism). 
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Exo/endocytotic assay 
The endocytosis assay to monitor SV recycling was performed using rabbit polyclonal 
antibodies directed against the intravesicular domain of synaptotagmin1 (Synaptic 
System), applied for 5 min at RT on the cultures, as described previously [30]. Incubations 
with the antibody (1:400) were performed in Tyrode solution containing 124 mM NaCl, 
5mM KCl, 2mM MgCl2, 30mM glucose, 25 mM HEPES, pH 7.4 and 2mM CaCl2.  After 
fixation and permeabilization, a synaptophysin counter staining with mouse anti 
synaptophysin, 1:400 (Sigma-Aldrich) visualized the totality of synaptic vesicles. Acquired 
images were processed and quantitatively analyzed with ImageJ software as previously 
described [47]. Briefly, cultures were infected at DIV4 with GPF expressing viruses and 
assayed at DIV14 as in [22]. GFP positive processes were manually tracked and the 
number of synaptotagmin and synaptophysin positive clusters and synaptophysin positive 
clusters present in the region of interest were automatically counted. 
 
Proteins digestion 
Approximately 2 µg of purified NSF pre-dephosphorylated with alkaline phosphatase 
(Promega) and subsequently phosphorylated or not with LRRK2 in the presence of 100 
µM ATP were loaded into a SDS-precasted gel (Biorad). Gel slices corresponding to 
purified NSF were excised, cut in smaller pieces, dehydrated with 100 µl of acetonitrile 
(ACN) for 10 minutes, then dried under vacuum. A protein reduction step was performed 
with 100 µl of freshly prepared 10 mM Dithiothreitol (DTT, Fluka) in 50 mM NH4HCO3, at 
56°C. After 1 h DTT solution was discarded and 100 µl of a freshly prepared solution of 55 
mM iodoacetamide (Sigma-Aldrich, St. Louis, MO, USA) in 50 mM NH4HCO3 was added to 
the gel pieces for 45 min at room temperature and in the dark. Gel pieces were washed 4 
times (ten minutes each) alternating 100 µl of 25 mM NH4HCO3 and 100 µl of ACN, dried 
under vacuum, and suspended in 20 µl of a sequencing grade modified trypsin solution 
(Promega, 12.5 ng/mL in 25 mM NH4HCO3). Digestion was performed overnight at 37°C. 
Peptides were extracted with 3 changes (50 µl each) of 50% ACN/0.1% formic acid (FA, 
Fluka). Samples were dried under vacuum and stored at -20 °C till the phosphopeptide 
enrichment procedure was performed. 
 
Enrichment of Phosphopeptides 
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Phosphopeptides were enriched with home made micro-columns of TiO2 as previously 
described [48]. TiO2 micro-columns were conditioned twice with 50 µl of ACN and twice 
with loading buffer (80% ACN/6% trifluoroacetic acid (TFA, Riedel-de Haën)). Samples 
were suspended in 50 µl of loading buffer and slowly loaded into the columns, which were 
then washed twice with 50 µl of loading buffer and twice with washing buffer (0.1% TFA). 
Phosphopeptides bound to TiO2 were eluted with 50 µl of freshly prepared 5% NH4OH and 
subsequently with 50 µl of 50% ACN/0.1% FA. Samples were immediately acidified by 
adding 5 µl of 100% FA and dried under vacuum.   
Mass spectrometry analysis 
Mass spectrometry analysis of phosphopeptides was performed with a LTQ-Orbitrap XL 
mass spectrometer (Thermo Fisher Scientific) coupled online with a nano-HPLC Ultimate 
3000 (Dionex-Thermo Fisher Scientific). Samples were dissolved in 30 µl of 3% ACN/0.1% 
FA and for every analysis 8 µl of sample were loaded at a flow rate of 8 µl/min into a trap 
column (300 mm I.D., 300 Å, C18, 3 mm; SGE Analytical Science). Samples were injected 
into a home-made 10 cm pico-frit capillary column (75 Pm I.D., 15 Pm tip; New Objective) 
packed with C18 material (Aeris Peptide 3.6 um XB-C18, Phenomenex). Peptides were 
separated using a linear gradient from 3% to 40% of ACN/0.1 FA in 20 min at a flow rate of 
250 nl/min.  
To increase the confidence in the identification of phosphopeptides, the MS analysis of 
each sample was performed with 3 different acquisition methods, as reported in [49]. A 
MS2 data dependent acquisition (1 full-MS scan in the range 300-1700 Da on the Orbitrap 
with a resolution of 60000, followed by MS/MS spectra acquired in the linear ion trap for 
the 10 most abundant ions); a MS3 neutral loss-triggered dependent acquisition (1 full-MS 
scan on the Orbitrap, followed by MS/MS scans on the 3 most intense ions and by MS3 
upon detection of neutral loss of phosphoric acid in MS2 spectra); a Multi Stage Acquisition 
(MSA) (1 full-MS scan at a resolution of 60000 followed by MS/MS scans on the 3 most 
abundant ions with the activation of neutral loss product without an additional isolation 
cycle).  
Raw data files were analyzed with Proteome Discoverer software (version 1.4, Thermo 
Fisher Scientific) connected to a Mascot Server version 2.2.4 (Matrix Science, UK) and a 
SequestHT search engine version 28.0 (Thermo Fisher Scientific) against the Uniprot 
Human Database (version 2013.11.13 used by SequestHT, version 2014.04.16 used by 
Mascot). Trypsin was set as digesting enzyme with up to 2 missed-cleavages. 
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Carbamidomethyl cysteine was set as fixed modification, while phosphorylation of 
Ser/Thr/Tyr and methionine oxidation were set as variable modifications. Peptide and 
fragment tolerance were 10 ppm and 0.6 Da respectively. Percolator was used to calculate 
False Discovery Rate (FDR) based on the search against the corresponding randomized 
database. MS/MS spectra of phosphopeptides were manually inspected for confirmation 
and assignment of phosphorylation sites. 
 
ATPase enzymatic assay  
NSF ATPase activity was quantified using the Malachite Green Assay by measuring the 
release of inorganic phosphate (Pi) due to the ATP hydrolysis with spectrophotometer. The 
assay was adapted from the method of Lanzetta et al. [50]. The Malachite Green Stock 
solution used for the assay was a mixture of two different solutions (one with 34 mg 
Malachite Green oxalate salt (Sigma-Aldrich. St. Louis, MO, USA) into 40 ml HCl 1M and 
the other with 1 g (NH4)2MoO4 (Sigma-Aldrich, St. Louis, MO, USA) into 14 ml HCl 4M to a 
final volume of 100 ml with distilled water and then filtered through 0,45 nm. The 
concentration of human NSF used for the ATPase assay was 216 nM (36 nM hexameric 
concentration) with different ATP concentration. Reaction was performed at 37°C and 
followed for 120 minutes. The time point aliquots collected (20 µl) were mixed with 150 µl 
of Malachite Green stock solution until the solution became homogenous and the 
absorbance measured at 640 nm using a corresponding Malachite Green solution as 
blank. The values of absorbance were then converted into µmol of free Pi in solution using 
a standard curve. To reported values for the kinetic constants (Km, kcat and Vmax) were 
obtained by data fitting with the Michaelis-Menten kinetic model (Y = Vmax*S/(Km + [S])).  
 
Reverse-phase HPLC ATPase assay 
To determine the ATPase activity of NSF, 500 or 700 µM ATP was added to 0.2 µM 
3xFlag-NSF wt. Proteins were purified as previously described and incubated at 37°C for 1 
hour in the same kinase buffers and conditions of the Malachite Green Assay. At the 
reported time-points, aliquots (20 µl) were taken up to 120 minutes and heated for 3 
minutes at 95°C with 0.1 M of EDTA to stop the reaction. Samples were stored at -80°C. 
Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) was used to 
monitor the amount of ATP and ADP present in the sample. Nucleotides were separated 
on a Jupiter 5u C4 300A (Phenomenex) column using an Agilent HP 1100 HPLC, pre-
equilibrated with 50 mM NaH2PO4 pH 6.5, 10 mM Tetra-n-butylammonium bromide and 
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4% ACN. The flow-rate used was 0.5 ml/min and the amount of the nucleotides was 
monitored measuring the increase in area of the peak corresponding to ADP measured at 
256 nm with a total run time of 35 minutes. To convert this value to the Pi released by the 
reaction, a standard curve generated with different ADP concentration was used. ADP 
concentrations detected in the assay were plotted as a function of time and an equation 
was obtained through linear regression with GraphPad Prism 5. 
 
Recombinant alpha SNAP and SNARE proteins production  
Rat alpha-SNAP cloned in pET28 plasmid in fusion with a His-tag was a kind gift of Dr. 
Reinhard Jahn, Max-Planck-Institute, Göttingen). Alpha-SNAP was subsequently 
expressed in E. Coli in BL21(DE3) strain. Bacteria were grown at 37°C to an OD at 600nm 
of 0.4-0.6, then induced with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 
hours. Cells were then harvested by centrifugation and the pellet of 250 ml of culture was 
resuspended in 5-10 ml of Tris-HCl pH 8.0. Phenylmethylsulfonyl fluoride (PMSF) 100μ M 
and a cocktail of protease inhibitors were added to the cells 1:100 (v/v) that were 
subsequently subjected to one French Press cycles (Constant Systems Ltd). The cell 
homogenate was centrifuged and the supernatant loaded onto a Co2+ affinity column and 
eluted with a 0-500 mM linear gradient of imidazole at 0.5 ml/min. Protein solution was 
dialyzed versus Tris-HCl 20 mM pH 7.5, NaCl 150 mM.  
Soluble SNARE complex was obtained by co-expression of wild type SNAP-25A, of 
syntaxin-1A and of His-tagged VAMP2(1-96) using the Duet expression system (Novagen) 
in E. Coli in BL21(DE3) strain. VAMP2(1-96)-His6-TEV pACYC-Duet and syntaxin-
1A/SNAP-25A pET-Duet were a kind gift of Prof. A. Brunger (Stanford University, 
California) [51]. Bacteria were grown at 37°C to an OD at 600nm of 0.6-0.8, then induced 
with 0.5 mM IPTG for 4 hours. Cell pellets of 250 ml of culture were suspended in 10 ml of 
50 mM NaPi, pH 8.0, 300 mM NaCl, 20 mM imidazole and 0.5 mM Tris(2-
carboxyethyl)phosphine (TCEP) (SNARE buffer), supplemented with PMSF 100 µM and 
protease inhibitors cocktail. Cell were lyses by two French Press cycles (Constant 
Systems Ltd) and the lysate was clarified by centrifugation for 1 hour at 15000g at 4°C. 
The supernatant was loaded onto a 1-ml Ni2+ affinity column, washed with 20 ml of 
SNARE buffer containing 7.5 M urea and then with 20 ml of SNARE buffer. The complex 
was then eluted with SNARE buffer containing 350 mM imidazole. After elution, SNARE 
complex was subjected to size exclusion chromatography using a Superdex 200 10/300 
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(GE Helthcare) that was equilibrated with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl. The 
SNARE complex was checked and quantified by SDS-PAGE. 
 
SNARE dissociation assay  
As previously described [51] the SNARE dissociation assays were performed at 37°C in 
240 µl in a 1.5 ml micro-tube. The assay buffer was composed of 25 mM Tris-HCl pH 7.5, 
5 mM β–glycerophosphate, 2 mM dithiotreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl2 and 
0.007% polysorbate 20. Subsequently 1.5 µM αSNAP, 480 nM SNAREs, 24 nM NSF 
(hexameric concentration) phosphorylated or not by LRRK2 (ratio NSF:LRRK2 20:1) were 
added in the presence of 2 mM ATP to start the reaction. At defined time points, an aliquot 
(20 µl) was collected and loaded into an SDS-PAGE gel without boiling the samples: being 
the SNARE complex is SDS-resistant, it runs as a single band on SDS-PAGE gel. The 
intensity of each SNARE complex band was calculated and normalized to its time zero. 
The experiments were performed in triplicate up to 150 minutes of reaction. 
 
Circular Dichroism (CD) 
CD measurements were carried out on a JASCO J-810 spectropolarimeter interfaced with 
a personal computer. The CD spectra were acquired and processed using the J-700 
software for Windows. All experiments were done at room temperature using an optical 
path length of 0.2 cm. The wavelength range of the measurements was 197–250 nm, 
using a bandwidth of 2 nm and a time constant of 8 s at a scan speed of 50 nm/min. The 
signal to noise ratio was improved by accumulating four scans. Spectra were acquired 
using purified proteins in the elution buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl and 
0.007% polysorbate-20) using the same buffer with 3xFlag peptide as a control. All the 
spectra are reported in terms of mean residue molar ellipticity (deg cm2 dmol−1). Protein 
concentrations in the samples were determined by SDS-PAGE and all the spectra were 
normalized for the measured protein concentration. 
 
Intrinsic fluorescence 
Fluorescence emission spectra were recorded on a Cary Eclipse fluorescence 
spectrophotometer (Varian, Agilent Technologies, Santa Clara, CA) using the Cary Eclipse 
program. Sample measurements were carried out using optical path length of 10 mm. 
Fluorescence spectra were obtained using an excitation wavelength of 288 nm, with an 
excitation bandwidth of 5 nm and slit width of 10 nm. Emission spectra were recorded 
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between 300-400 nm at a scan rate of 30 nm/sec. Spectra were acquired using 80 nM 
proteins in 20 mM Tris/HCl buffer (pH 7.5), 150 mM NaCl and 0.02% Tween 20. 
 
Statistical analysis 
All quantitative data are expressed as mean ± SEM and represent at least three 
independent sets of experiments. Significance of differences between two groups was 
assessed by two-tailed unpaired t-test or one-way or two-way ANOVA with Bonferroni’s 
post-test when more than two groups were compared. Significance was set at p<0.05. 
 
Abbreviations 
NSF: N-ethylmaleimide sensitive fusion  
LRRK2: Leucine-rich repeat kinase 2 
SNARE: soluble NSF-attachment protein receptor 
PD: Parkinson’s disease 
ANOVA: Analysis of variance 
TBS: Tris-buffered saline 
SV: synaptic vesicles 
sypHy: synaptophysin-pHluorin  
CD: Circular Dichroism  
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Figure legends 
 
Figure 1. LRRK2 kinase activity modulates synaptic vesicle fusion. 
(a) We recorded synaptophluorin fluorescence from DIV14 wild-type cortical neurons 
treated with DMSO (control) or treated with LRRK2 inhibitor GSK2578215A (GSK in, 0.2 
PM, 2h) and from cortical neurons obtained from BAC hG2019S mice (hG2019S). 
Representative snapshots were taken at DIV16 from 1 Hz recordings at rest (0), after 40 
action potential stimulation (40AP), after 300 action potential stimulation (300AP) and upon 
neutralization with 50 mM NH4Cl to reveal total fluorescence (Fmax). Panels size is 
113x113 μm. (b) The graph shows representative pattern of fluorescence. Y-axis reports 
ΔF/F0 at the given time point (second). (c) The graphs report the increase in fluorescence 
after 40AP (ΔF40/F0) and 300AP (ΔF300/F0) and the kinetic of signal after 300AP 
expressed as time constant describing the increase (tau upstroke) and decay (tau decay) 
of fluorescence. Data are expressed as mean ± SEM, n=4, at least 50 boutons from 
minimum 5 neurons were analyzed for experiment (* p<0.05; ** p<0.01 versus control, 
ANOVA). (d) The exo/endocytotic assay was performed at DIV14 on wild-type and BAC 
hG2019S cortical neurons infected at DIV4 with virus expressing GFP. Cycling SV 
appears as synaptotagmin (s-tagmin) positive clusters along neuron processes. Total SV 
pool was revealed by staining with anti-synaptophysin antibodies upon fixation and 
permeabilization. Images show signals acquired for synaptotagmin, synaptophysin and 
their superimposition plus GFP (merge). Panel size is 28 x 4 Pm. (e) The percentage of s-
tagmin and s-physin positive clusters within the totality of s-physin positive clusters reflects 
the pool of cycling vesicles. Data are expressed as mean ± SEM, n=4, at least 7 neurons 
were analyzed for experiment (** p<0.01 Student's t-test). 
 
Figure 2. LRRK2 interacts with NSF 
(a) Extracts of purified cortical synaptosomes were incubated with anti-LRRK2 antibodies 
or rabbit IgG. The immunocomplexes were sedimented with protein G-Sepharose and the 
samples were resolved by SDS-PAGE and analyzed by immunoblotting with anti NSF and 
anti LRRK2 antibodies. Immunoblotting against synaptotagmin 1 (S-tagmin1), 
synaptophysin (S-physin) and synaptobrevin (S-brevin) were performed to confirm purity of 
synaptosomal preparation. (b) Flag-NSF full-length or domains (N, D1, D2) purified from 
HEK293T and bound to M2 flag resin were incubated with a mouse brain lysate. Samples 
were subjected to immunoblotting using anti-LRRK2 (MJFF2) or stained with Coomassie 
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to show flag inputs. (c) Size exclusion chromatography fractions of HEK293T expressing 
ectopic flag-NSF alone or together with 2xMyc-LRRK2 spotted onto nitrocellulose 
membrane and probed with anti-flag antibody (n=3 independent experiments). (d) 
Immunofluorescence of primary cortical neurons stained for endogenous LRRK2 and 
endogenous NSF (scale bar is 10 µm).  
 
Figure 3. LRRK2 phosphorylates NSF.  
(a) In vitro radioactive kinase assays of 3x-Flag LRRK2 wild-type, K1906M (kinase dead) 
and G2019S (hyperactive) and flag-NSF purified from HEK293T cells at 1:10 ratio. 
Radioactivity incorporated was revealed by autoradiography (upper panel) and total 
proteins loaded by flag immunoblotting (lower panels). LRRK2 inhibitor IN-1 was used at 1 
µM concentration to confirm LRRK2 specific phosphorylation on NSF. (b) In vitro kinase 
assays as in (a) with the hyperactive GST-LRRK2970-2527 fragment. (c) Quantification of 
moles of 33P incorporated by NSF using a calibration curve with known concentration of 
33P-ATP. (d) In vitro kinase assays as in (a) using NSF full-length or domains as 
substrates of LRRK2 GST-LRRK2970-2527 kinase activity at 1:10 ratio LRRK2:NSFs. 
Radioactivity incorporated was revealed by autoradiography (upper panel) and total 
proteins loaded by coomassie brilliant blue (CBB) staining for NSF (middle panel) or 
LRRK2 immunoblotting (lower panel). (e) In vitro radioactive kinase assays of 3xFlag-
LRRK1 or 3xFlag-LRRK2 and Flag-NSF as substrate at 1:10 ratio. Left panel is an 
example of autoradiography and right panel represents the corresponding immunoblot of 
total loading.  
 
Figure 4. LRRK2 phosphorylates NSF at T645. 
(a) In vitro kinase assays with 3xFlag-LRRK2 G2019S and NSF wild-type or non-
phosphorylatable mutants T645A, T646A and S647A mutants at 1:10 ratio LRRK2:NSF. 
The G2019S hyperactive mutant was used to maximize 33P incorporation. (b) 
Quantification of 33P incorporated by NSF (autoradiography, upper panel) controlled for 
total NSF (NSFTOT, coomassie staining, lower panel) from n=4 independent experiments 
(bars represent the mean ± SEM). One way-ANOVA with Bonferroni’s post-test (**p<0.01). 
 
Figure 5. Phosphorylated NSF exhibits enhanced ATPase activity. 
(a) NSF ATPase activity was assessed with a Malachite green assays at 36nM NSF and 
increasing concentrations of ATP substrate (up to 1.4 mM) in the presence of NSF alone, 
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NSF pre-phosphorylated by LRRK2-G2019S970-2527 ('G2019S) or LRRK2-G2019S970-2527 
('G2019S) alone (NSF:LRRK2 20:1). Data were fitted with the Michaelis-Menten kinetic 
model to determine kinetic constants. (b) Phosphate generated by ATP hydrolysis in the 
presence of NSF wild-type, NSFT645A NSFT646A NSFS647A pre-phosphorylated or not by 
'G2019S was measured with the Malachite Green Assay at 120 min with an initial 
concentration of ATP of 1.4 mM (NSFWT vs NSFT645A **p<0.01; NSFWT vs P-NSFWT 
***p<0.001; NSFT645A vs P-NSFT645A p>0.05, non significant, n.s.; NSFT646A vs P-NSFT646A 
p>0.05, n.s.; NSFS647A vs P-NSFS647A **p<0.01; one-way ANOVA, Bonferroni’s post-test, 
n≥3). UT=untrasfected cells subjected to Flag-affinity purification to monitor background 
activity (n=1; excluded from the statistical analysis). 
 
Figure 6. Phosphorylated NSF exhibits increased rate of SNARE complex 
disassembling in vitro. 
(a) Representative coomassie gels (CBB, coomassie brilliant blue) of SNARE complex 
incubated for increasing time with NSF phosphorylated or not by LRRK2-G2019S970-2527 in 
the presence of the co-factor alpha-SNAP. (b) Quantification of n=3 independent 
experiments. Time points are relative to t=0 which was set at 100% (two-way ANOVA with 
Bonferroni’s post-test, ***p<0.001).   
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